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Abstract
Assembly of spliceosome snRNPs requires a megadalton molecular machine called the survival of motor
neuron (SMN) complex. In higher eukaryotes, this complex consists of SMN, Gemins2-8 and unrip.
Deficiency in SMN causes spinal muscular atrophy (SMA), a leading cause of heritable mortality in infants
and children. The mechanism of precisely how seven Sm proteins are arranged in a ring around an
snRNA, to form a snRNP was not well understood, due in part to the large number of components and
heterogeneity of the SMN complex. Through use of several techniques including: RNA gel-shifts, pulldowns, F�rster resonance energy transfer, ultracentrifugation, electron microscopy, molecular modeling
and genetic manipulation in simple model organisms and human cells, this area was illuminated. Here I
will present evidence for Sm5 dependent association of Gemin2 with SMN. Through a series of
hydrophobic interactions between amino and carboxy termini, binding of Sm protein to Gemin2 opens a
binding site for SMN on its distal side, in both human and S. pombe. I will prove that human SMN
complexes in cells require Gemin8 to form large oligomers. I will demonstrate that the oligomerization
state of S. pombe SMN is a tetramer, and visualize its complete SMN complex. I will show that both S.
pombe and S. cerevisiae SMN-Gemin2 and Brr1 are sufficient for snRNP assembly from recombinant
sources. I will further show that S. cerevisiae Brr1 is capable of binding all substrates of the SMN
complex. Through genetics I demonstrate a toxicity from Gemin2, when its levels exceed SMN capacity in
S. pombe. Finally, I will suggest that the imbalance of Gemin2 and SMN occurs in the devastating
childhood disease, SMA, and is a contributing factor. These results amount to a paradigm shift wherein
Gemin2 usurps SMN as the most important member of the now SMN-Gemin2 complex for snRNP.
Furthermore, with toxicity of excess Gemin2 relative to SMN and the likelihood of this occurring in SMA
patients, Gemin2’s position of importance as a potential therapeutic target in SMA has been revealed.
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ABSTRACT
THE GEMIN2 COMPLEX: AN EVOLVING VIEW OF SMN MEDIATED SNRNP
ASSEMBLY
Eric S. Babiash
Gideon Dreyfuss
Assembly of spliceosome snRNPs requires a megadalton molecular machine called the
survival of motor neuron (SMN) complex. In higher eukaryotes, this complex consists of
SMN, Gemins2-8 and unrip. Deficiency in SMN causes spinal muscular atrophy (SMA), a
leading cause of heritable mortality in infants and children. The mechanism of precisely
how seven Sm proteins are arranged in a ring around an snRNA, to form a snRNP was not
well understood, due in part to the large number of components and heterogeneity of the
SMN complex. Through use of several techniques including: RNA gel-shifts, pull-downs,
Förster resonance energy transfer, ultracentrifugation, electron microscopy, molecular
modeling and genetic manipulation in simple model organisms and human cells, this area
was illuminated. Here I will present evidence for Sm5 dependent association of Gemin2
with SMN. Through a series of hydrophobic interactions between amino and carboxy
termini, binding of Sm protein to Gemin2 opens a binding site for SMN on its distal side,
in both human and S. pombe. I will prove that human SMN complexes in cells require
Gemin8 to form large oligomers. I will demonstrate that the oligomerization state of S.
pombe SMN is a tetramer, and visualize its complete SMN complex. I will show that both
S. pombe and S. cerevisiae SMN-Gemin2 and Brr1 are sufficient for snRNP assembly from
recombinant sources. I will further show that S. cerevisiae Brr1 is capable of binding all
substrates of the SMN complex. Through genetics I demonstrate a toxicity from Gemin2,
when its levels exceed SMN capacity in S. pombe. Finally, I will suggest that the imbalance
of Gemin2 and SMN occurs in the devastating childhood disease, SMA, and is a
contributing factor. These results amount to a paradigm shift wherein Gemin2 usurps SMN
as the most important member of the now SMN-Gemin2 complex for snRNP. Furthermore,
with toxicity of excess Gemin2 relative to SMN and the likelihood of this occurring in
SMA patients, Gemin2’s position of importance as a potential therapeutic target in SMA
has been revealed.
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Introduction
RNA Splicing, and Spliceosomal snRNPs
Eukaryotic genes are transcribed from genomic DNA as large sequences of RNA
containing

both

protein

coding

and

non-coding

sections

initially

as

pre-

mRNA.(Anonymous, 2001; Johnson et al., 2003) The non-coding space between coding
regions is termed an intron whereas the remainder, the protein coding as well as 5’ and 3’
untranslated regions (UTR) are contained within exons.(Tarn and Steitz, 1997) Introns
must be removed before the ribosome uses the mature mRNA to make functional
protein.(Matlin et al., 2005) The megadalton molecular machine responsible for the
removal of these introns is a RNA-protein particle (RNP), the spliceosome. The key and
catalytic components of spliceosomes are U-type small nuclear RNPs (snRNPs). All
snRNPs are composed of specific proteins as well as seven shared proteins of very similar
structure together called either Sm proteins (or related Lsm proteins) that form a ring
around a small specific sequence of the small nuclear RNA (snRNA).(Black, 2003;
Papasaikas and Valcárcel, 2016; Tarn and Steitz, 1997; Wahl et al., 2009) Through use of
snRNPs in splicing, eukaryotic cells are able to achieve unparalleled levels of regulation
and modification.
Perhaps the single greatest advancement in eukaryotic evolution was the ability to pick and
choose which parts of genetic information were used. Initially this was largely binary, only
choosing exons to include and introns to remove, but later when, where, and how often
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these exons, termed alternative exons, would be included also became regulated.(Francisco
E Baralle and Jimena Giudice, 2017; Iñiguez and Hernández, 2017; Wang et al., 2008) Use
of exons, which would ultimately code for protein and introns gave the cell the ability to
put regulatory elements mid gene without disrupting the function of the protein they coded
for. The exonization of mRNA also allowed for evolution to make a small change to one
copy of a gene which would create, change the size of, or remove an exon dramatically
changing the coded protein’s function.(Daniel et al., 2015; Nilsen and Graveley, 2010)
Further advancements, seen ubiquitously in cordates, are the ability to pick and choose
alternative exons based on need or tissue type(Francisco E Baralle and Jimena Giudice,
2017; Gabanella et al., 2007; Wang et al., 2008) . These more advanced modes of
regulation, found increasingly more in higher eukaryotes, are one of the chief reasons why
there isn’t a huge increase in gene number as species became more complex.(Collins et al.,
2009; DePamphilis, 2016; Schubert and Vu) A model pre-mRNA and its splicing pattern
can be seen in figure 1.1.1. All of this wouldn’t be possible without the use of a very
complex RNA protein particle (RNP) composed itself of smaller RNPs: the spliceosome.
Removal of non-coding introns requires assembly of the spliceosome and many steps of
rearrangement and reorganization of its components, but at its base fundamentally requires
direct base pairing to sequences within the pre-mRNA: the 5’ splice site (5’ss) and the
branch point adenosine near the 3’ splice site (3’ss). In the spliceosome, recognition of
these sites and catalysis are accomplished through the snRNAs U1, U2, U4, U5 and U6
(major); and in the minor spliceosome cognates U11, U12, U4atac and U6atac both sharing
2

U5.(Brow, 2002; Nilsen, 2002; Papasaikas and Valcárcel, 2016; Staley and Guthrie, 1998;
Wahl et al., 2009; Will and Lührmann, 2011) The first step of splicing requires the
cotranscriptional association of U1 with the 5’ss and U2 with the BPS to form E
complex.(Sharma et al., 2005) Next, additional factors such as SR proteins associate with
the pre-mRNA, and U1 and U2 locate one another through helicases Prp5 and Sub2 to form
A complex.(Fleckner et al., 1997; Pleiss et al., 2007; Xu and Query, 2007) A tri-snRNP
of U4/5/6 associates with U1 and U2 bound pre-mRNA via Brr2 resulting in B
complex.(Ledoux and Guthrie, 2014; Schneider et al., 2010a; Small et al., 2006) Multiple
helicases then cause U6 to displace U1 on the 5’ss, and eject U4, moving to B act complex.
Finally, guided by U5 the adenosine in the BPS attacks the 5’ss cleaving it in two allowing
the exon side to in turn attack and attach to the 3’ss facing the exon. This results in an
intron lariat bound by U2, U5 and U6 to be free from the mRNA during multiple steps in
the C complex.(Ilagan et al., 2009; Schneider et al., 2010) The snRNPs are recycled and
tri-snRNP reassembled ready for another round of RNA splicing.(Brow, 2002; Burge, C B
C B, 1999; Konarska et al., 2006; Madhani and Guthrie, 1992; Nilsen, 2002; Staley and
Guthrie, 1998) Every step of the RNA splicing process critically requires the use of
different combinations of these snRNPs and is illustrated in figure 1.1.2.
For a long time, these spliceosomal snRNPs were thought to exclusively be involved in
cis-splicing within the spliceosome. There is now recognition that U1 snRNP can function
in an additional role independent of splicing, in the prevention of premature cleavage and
polyadenylation, termed telescripting.(Berg et al., 2012; Kaida et al., 2010; Wu and Sharp,
3

2013) U1 snRNP can also function together with splice leader RNA to assemble a transspliceosome between different genes; although this is very rarely seen in higher eukaryotes,
it is heavily utilized in T. brucei and C. elegans.(Sutton and Boothroyd, 1986; Yang and
Walsh, 2005) The precise mechanism of both of these reactions is an active area of research
and sure to yield even more and important insights into the critical role of snRNPs in gene
regulation and diversification. A non-spliceosomal, but structurally related snRNP, U7 is
critical for processing the unique pathway of histone mRNAs. U7 base pairs through its 5’
end with a histone recognition element enabling cleavage independent of the cleavage and
polyadenylation machinery used by all other mRNAs, and features a unique hybrid ring of
Sm / Lsm proteins.(Neuenkirchen et al., 2008; Reddy and Busch, 1981; Tisdale et al., 2013)
The identifying feature of a snRNP is a ring of seven similarly folded proteins around a
specific uracil rich site. In the case of U1, U2, U4 and U5, these proteins are Sm proteins
and the RNA site is referred to as the Sm site (AU2-4G/UUG), and for U6 the proteins are
related Lsm proteins and the site is AU5. Sm and Lsm proteins are small proteins containing
the Sm fold, a single alpha helix outside of a highly-twisted beta-sheet. In the Sm fold b1
to b4 run antiparallel b5 wrapping back around to contact b1. After b5, there is an
unstructured C-terminal tail which is longest in SmB, D1, D2, and D3 respectively and all
save SmD2 having arginine glycine repeat (RG) motifs which are symmetrically
dimethylated on arginine. In cells and in isolation, these Sm proteins exist in two
heterodimers and a heterotrimer of SmB/D3, SmD1/D2 and SmF/E/G. Each Sm protein
contacts one or two bases in the Sm site and interacts directly with a neighboring Sm
4

protein through a b4 to b5 beta-sheet interaction. The interaction of these Sm proteins with
each other forms a very tight bond which is stable under high detergent and high salt
conditions when bound to RNA.(Bach et al., 1990; Guthrie and Patterson, 1988; Heinrichs
et al., 1992; Kambach et al., 1999; Kondo et al., 2015; Leung et al., 2011; Li et al., 2016;
Newman and Nagai, 2010; Weber et al., 2010) The beta-beta interaction closes on itself
to form a ring around the Sm site, with is only removable by the proteolysis of Sm proteins
or the activity of a nuclease allowing them to slide off. The structure of U4 snRNP’s Sm
core is shown in figure 1.1.3. This Sm ring can spontaneously form on most uracil rich
elements resembling an Sm site in vitro when the seven Sm proteins are present, but this is
not the case in vivo. Cells must specifically assembly Sm cores only on Sm sites and given
the high probability of uracil sequences occurring in non-snRNAs and the seemingly
immovable nature of Sm rings, they require assembly chaperones. This is facilitated by a
component of the methylosome, plCln and the survival of motor neuron (SMN) complex
until the SMN complex specifically recognizes snRNA and then assembles the Sm
ring.(Bach et al., 1990; Grimm et al., 2013a; Heinrichs et al., 1992; Liu et al., 1997;
Paushkin et al., 2002; Pellizzoni et al., 2002; Raker et al., 1999)

5

Figure 1.1.1 Architecture of pre-mRNA and possible splicing
Scheme showing model pre-mRNA contains both introns (shown as a narrow grey line)
and exons (colored boxes). Exons always included in mature mRNA shown are constitutive
exons (blue), alternative exons (green) and a special type of alternative exon a cassette
exon (orange). Shown in dashed lines is the splice pattern yielding the mRNA shown above
or below. Intron and exon size are not shown to scale, introns are typically much larger
than exons.
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Figure 1.1.2 Spliceosome mediated splicing of pre-mRNA
Shown are the steps of spliceosome assembly on and splicing of pre-mRNA. Shown first
is newly transcribed pre-mRNA onto which E complex assembles, followed by B and B
ACT complexes finally passing to C complex after which mature mRNA and a lariat from
the intron are released. Note the essential sequences at the 5’ and 3’ ends of exons as well
as the branch point adenosine. Highlighted are the U snRNPs with their RNA components
preforming the catalysis of splicing. Key to each snRNP is a set of Sm (light green) or Lsm
(dark green) proteins in a core shown on the figure. Adapted from Patel and Steitz.(Patel
and Steitz, 2003)
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Figure 1.1.3 Structure of the Sm core on U4 snRNA
Shown below is a crystal structure of the core of human U4 snRNP. Seven Sm proteins
form a ring or core around the Sm site of the snRNA (light blue). The Sm proteins each
contact one another in this ring through a b-b interaction and contact 1-2 nucleotides of the
Sm site in the following order SmE (teal), SmG (orange), SmB (dark red), SmD3 (purple),
SmD1 (green), SmD2 (yellow, and SmF (pink). PDBID: 4WZJ Adapted from Leung,
Nagai, and Li(Leung et al., 2011)
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The SMN Complex
As some of the most important molecules in an eukaryotic cell, snRNPs require a robust
and specialized assembly machine; this is accomplished by the survival of motor neuron
(SMN) complex.(Cauchi, 2010; Fischer et al., 1997; Pellizzoni et al., 2002a) Containing
survival of motor neuron (SMN) protein as well as up to eight additional proteins (Gemins
2-8 and unrip) in humans the SMN complex is both very large and complex, slowing the
pace of understanding it.(Gubitz et al., 2002; Carissimi et al., 2005; Carissimi et al., 2006;
Charroux et al., 2000; Fischer et al., 1997; Baccon et al., 2002; Pellizzoni et al., 2002a;
Pellizzoni et al., 2002b; Cauchi 2002) SMN is the core scaffold of the complex and
contains domains required for association of some of the Gemins; substrates Sm proteins
and snRNA; and for self-oligomerization.(Liu et al., 1997; Paushkin et al., 2000; So et al.,
2016; Wan et al., 2005) SMN together with Gemin2 are the most ancient core components
and can bind all substrates for Sm core formation.(Paushkin et al., 2000; Cauchi, 2002)
Although SMN and most of the Gemins are found in the nucleus, the initial snRNP
assembly steps from nascent snRNA happen in the cytoplasm despite living the rest of their
lives in the nucleoplasm.(Matera and Frey, 1998; Cauchi, 2002)
The Sm protein containing snRNPs U1, U2, U4 and U5 along with their minor spliceosome
counterparts and U7 have their Sm rings added to them by the SMN complex.(Fischer et
al., 1997; Pellizzoni et al., 2002a; Tisdale et al., 2013) The first step to making a snRNP
is to transcribe a pre-snRNA through initiation of RNA pol II via the specialized SNAP
complex.(Boyd et al., 2003; Egloff et al., 2008; Mattaj et al., 1993; Meister and Fischer,
12

2002; Nigg et al., 1991) The pre-snRNA is quickly capped with m7G which is recognized
by PHAX and shuttled it to the cytoplasm.(Guthrie and Patterson, 1988; Ohno et al., 2000)
Upon entering the cytoplasm, the pre-snRNA is exchanged off of PHAX on to the SMN
complex component Gemin5.(Yong et al., 2010) Gemin5 associates with and delivers the
pre-snRNA to the SMN complex containing the remaining Gemins as well as all seven Sm
proteins.(Battle et al., 2006a; Cauchi, 2010; Lau et al., 2009; Yong et al., 2010) . After
translation, all seven Sm proteins are first delivered to the methylosome with SmB, D1 and
D3 being symmetrically dimethlated on arginines in their C-terminal tails, and escorted to
the SMN complex by methylosome component plCln.(Brahms et al., 2001; Friesen et al.,
2001a; Friesen et al., 2001b; Friesen et al., 2002; Paushkin et al., 2002) Now on the SMN
complex, Sm proteins assemble a ring around the Sm site of the snRNA, in a mechanism
that is as of yet unclear, but requires all Gemins and ATP. Following ring assembly, the
pre-snRNA cap is hyper methylated to m2,2,7G by TGS1, the 3’ end is trimmed to mature
length snRNA and the SMN complex dissociates.(Borg et al., 2016; Mouaikel et al., 2002;
Sloan et al., 2016) The now mature snRNP is imported to the nucleus via snurportin-1,
where additional factors may assemble and the mature snRNP is ready to function in
splicing or telescription.(Kaida et al., 2010; Kühn-Hölsken et al., 2010; Papasaikas and
Valcárcel, 2016; Paraskeva et al., 1999) For most snRNP specific proteins, it is unclear
when in the maturation process they associate; however, for one, U1-70K we know it can
uniquely recruit pre-U1 snRNA to the SMN complex independent of Gemin5 binding
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before Sm ring formation.(Battle et al., 2006b; Lau et al., 2009; So et al., 2016) This
process is illustrated in figure 1.2.1, and is heavily dependent on SMN protein.
The founding and most important member of the SMN complex is SMN. Mutations or
deletions in SMN gene copies result in the devastating disease spinal muscular atrophy
(SMA).(Kolb and Kissel, 2015; Wan et al., 2005) SMN in most eukaryotes contains
several important domains, Gemin2 binding domain, Tudor domain, polyproline region,
and arguably the most important the tyrosine-glycine box (YG-box). The most N-terminal
domain is a short alpha helix responsible for binding to the complex’s most conserved
component Gemin2.(Sarachan et al., 2012; Zhang et al., 2011) It is followed by a region
that has non-specific RNA binding capacity although it is not known to what extent this is
utilized in snRNP Sm ring formation.(Bertrandy et al., 1999) In the middle of the protein
is the tudor domain which is responsible for binding to methylated arginines with increased
specificity for symmetric dimetylation seen in the tails of SmB, D1 and D3.(Brahms et al.,
2001; Sprangers et al., 2003; Wan et al., 2008) The next region is a large poly-proline
region that expanded in size considerably with evolution and the function of which remains
undetermined. The final domain is one of the most studied as it is unique, a mutation hot
spot, and responsible for SMN-SMN oligomerization through which many processes
function.(Burghes and Beattie, 2009; Takarada et al.) It is the final YG-Box that is partially
truncated in mRNAs lacking exon 7, where the final amino acids (279-294) are replaced
with the amino acids EMLA (SMN∆7); this results in an SMN which cannot oligomerize
and the sequence, termed a degron, causes this SMN to be rapidly proteolyzed.(Chang et
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al., 2004; Cho and Dreyfuss, 2010; Le et al., 2005) The YG-Box is a domain unique to
SMN sequence where tyrosine glycine repeats in an extended alpha helix afford very tight
helix-helix packing with one another allowing for oligomerizatoin.(Martin et al., 2012) A
multiple sequence alignment of SMN shows this domain architecture in figure 1.2.2. Much
of the effort in trying to fix SMN deficiency has focused on stabilizing SMN∆7 and
enabling some snRNP assembly albeit less than wildtype protein.
The most conserved member of the SMN complex is Gemin2. Gemin2 can be found in
eukaryotes back to budding yeast where it is called Brr1 and seemingly functions in snRNP
assembly without an SMN ortholog.(Fischer et al., 1997; Noble and Guthrie, 1996a; Noble
and Guthrie, 1996b; Schwer et al., 2017) Gemin2 contacts SmF/E/G through a conserved
helix in its extended N-terminal domain while simultaneously contacting SmD1/D2
through loops in its C-terminal helical bundle. Through these domains Gemin2, brings the
two sets of Sm proteins together, creating a crescent shaped pentamer of SmD1/D2/F/E/G
(Sm5). The very amino terminus of Gemin2 is also sufficient to interact with an open cleft
in Sm5 where snRNA would sit and block RNA binding to Sm proteins, effectively
chaperoning them until an undetermined factor in the SMN complex allows the snRNA to
enter. Sm5 can be docked onto Gemin2 with methylosome component plCln or separately
and the pentamer is held in a slightly strained squeeze which would not easily allow
SmB/D3 in to close the Sm ring. Through the distal side of its C-terminal domain, Gemin2
also binds a short sequence of SMN, termed the Gemin2 binding domain, in a highly
hydrophobic cleft.(Grimm et al., 2013; Sarachan et al., 2012; Zhang et al., 2011) A crystal
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structure of this complex is shown in figure 1.2.3. This interaction is thought to be very
strong and is disrupted when SMN carries a disease-causing mutation D44V, or when a
cognate mutation R213D is made in Gemin2. Gemin2 seems to largely associate with the
remaining SMN complex components through SMN, although possible links to Gemin5
have been shown and Gemin6 and 7 are theorized to take plCln’s place in the
complex.(Cauchi, 2010; Grimm et al., 2013b; Ma et al., 2005; Zhang et al., 2011) In vitro
studies showed that Gemin2 and SMN alone are sufficient for snRNP assembly and are the
only components found in primitive eukaryotes such as S. pombe, leading to the conclusion
that these are the core components of the complex with the remaining filling in regulatory
roles.(Mattaj, 1998; Paushkin et al., 2000)
The remaining components of the SMN complex can be roughly grouped into two different
subcomplexes: Gemin3/4/5 and Gemin6/7/8 with unrip. These appeared at different times
in eukaryotic evolution (Figure1.2.4).(Cauchi, 2010) Gemin3 is a DEAD box helicase, as
ATP is required of snRNP assembly and only Gemin3 is capable of hydrolysis, Gemin3
must unwind snRNA or otherwise restructure it for transfer to Sm proteins.(Charroux et
al., 1999; Wan et al., 2008) Gemin4 is a very large heat repeat protein which is thought to
be a scaffold on which Gemin3 and 5 associate and perhaps the means through which SMN
interacts with the Gemin3/4/5 subunit.(Borg et al., 2015; Charroux et al., 2000) Gemin5
is able to recognize not only the Sm site and m2,2,7G cap, but importantly a 3’ stem loop
just before the Sm site both regions together are called the snRNP code, and critical for
snRNAs delivery to the SMN complex.(Gubitz et al., 2002; Battle et al., 2006; Lau et al.,
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2009; Tang et al., 2016; Yong et al., 2010) Because of this, Gemin5 is the component of
the complex with the most discretion in what RNAs will have a Sm ring attached. Gemin8
links Gemin6 and 7 as well as the transient partner unrip to the SMN complex, but has
otherwise unknown functionality.(Carissimi et al., 2006) Gemins6 and 7 are small proteins
whose crystal structure revealed Sm folds, leading to speculation that they might act as
mock Sm proteins either for Gemin2-Sm5 binding or elsewhere.(Baccon et al., 2002;
Pellizzoni et al., 2002b; Ma et al., 2005) The most transient of the SMN complex
components, unrip, is largely known for its functions outside of SMN complex snRNP
assembly and knockdown of it does not have significant effect on Sm core formation like
most of the other components.(Carissimi et al., 2005) Mouse knockouts of SMN and
Gemins2-5, with 6-8 being untested, result in embryonic lethality, highlighting the fact that
the proteins of the SMN complex are critical for life.(Cauchi, 2010) Most important to
humans, loss of SMN protein function is the cause of a common and deadly motor neuronal
disease, SMA.
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Figure 1.2.1 SMN complex mediated snRNP assembly pathway
View of snRNP assembly pathway, prior to work presented here, whereby sections
showing Gemin2’s association to SMN as well as some steps in Sm core formation will be
modified and expanded upon. Pre-snRNAs are transcribed by RNA polymerase II and
exported to the cytoplasm through Phax and exportin1 as part of the cap binding complex.
After export, pre-snRNA is recognized due to its snRNP code by Gemin5, which together
with Gemins 3 and 4 bring it to the SMN complex. After translation, Sm proteins are
recruited to the methylosome with Sms B, D1, and D3 receiving symmetric demethylation
on their RG tails, a mark specifically recognized by SMN’s Tudor domain. SmF/E/G and
SmD1/D2 are formed in a pentamer by plCln and Gemin2 and then recruited to the SMN
complex. The snRNP core is assembled and the snRNA is trimmed to its mature length and
the cap is hypermethylated. Now a snRNP, it is imported to the nucleus by snurportin-1
where it can begin the splicing reaction and other pre-mRNA processing events. Adapted
from Yong et al.(Yong et al., 2010)
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Figure 1.2.2 Multiple Sequence Alignment of SMN
Multiple sequence alignment from 53 species SMN complexes using t-coffee expresso.
Shown are only representative organisms human, mouse, chicken, frog, worm, and fission
yeast (no SMN in brewer’s yeast). Above is shown position number for human SMN and
its four domains (Gemin2 BD, Tudor, poly-proline, and YG-Box) with their secondary
structures. High conservation is seen in darker shades of green with YG-Box and Gemin2
BD the most conserved. For ease of viewing proline expansion, prolines within the poly
proline region are colored blue. The four key aromatic residues of the Tudor domain are
highlighted in yellow and are present in most multicellular eukaryotes, but absent in yeasts.
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Figure 1.2.3 Crystal structure of Gemin2 bound to Sm5 and SMN peptide
X-ray diffraction determined crystal structure of human Gemin2 (red), SMN peptide (blue),
and Sm pentamer (SmD1 green, SmD2 yellow, SmF pink, SmE teal, and SmG orange;
colored as figure 1.1.3) is show in four rotations. The amino terminal domain of Gemin2
(NTD a.a. 1~64), adopts a highly-extended confirmation and contacts Sm5 pentamer
before blocking snRNA entry site. Gemin2’s carboxy terminal domain (CTD a.a. 80-280)
makes contacts with SmD1 an/D2 and on the distal face binds a short helix of SMN.
PDBID: 3S6N Adapted from Zhang et al.(Zhang et al., 2011)
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Figure 1.2.4 SMN complex components in selected species
Presence of SMN and Gemin components of the SMN complex in select eukaryotes is
indicated by a check mark in the corresponding column labeled with their name and a
cartoon from figure 1.2.1. Some of the components are putative, and research on some of
them, especially in amoeba and plant, require verification. Gemin2 is the most conserved
followed closely by SMN. Gemin4 is the least conserved appearing in chordates. Gemins
6-8 always appear together, and interestingly have no known orthologs in fly despite their
putative presence in both wasp and worm.
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Spinal Muscular Atrophy
Clinical diagnosis of a disease affecting young children characterized by muscle wasting
and ultimately death largely due to respiratory failure, has been known since
1891.(Werdnig, 1891) The disease progression would later be mapped, found to be a
simple heritable disease, and be termed spinal muscular atrophy (SMA) due to
degeneration of the anterior horn of the motor neuron. It was not until 1995 when Judith
Melki identified the genes responsible for SMA, SMN1 and SMN2 that work on the
molecular mechanism could begin.(Lefebvre et al., 1995) Through work pioneered by the
Dreyfuss lab SMN was found to be critically involved in snRNP assembly, and deficiency
in this function is still the leading theory for SMA pathogenesis. The possibility remains
that there are SMN effects outside of snRNP assembly as well, as SMN has been implicated
in an increasing and diverse set of RNPs and regulation of RNAs.
SMA affects 1 in 6000-10000 births and is the most common heritable neuro-muscular
disease.(Kolb and Kissel, 2015) SMA is characterized by a reduction in functional SMN
protein coming from two nearly identical genes, SMN1 and SMN2. These two gene copies
are only found in some primates including humans and differ by five nucleotides all but
one of which are intronic resulting in a single silent mutation in the mature mRNA. This
mutation however, causes pre-mRNA transcribed from SMN2 to produce an mRNA that
predominantly excludes the final coding exon, exon 7, which produces a short-lived,
dysfunctional protein.(Cho and Dreyfuss, 2010; Lorson and Androphy, 2000) In humans,
therefore a loss, mutation in, or conversion to SMN2 of SMN1 increasingly demands
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functional full-length SMN from SMN2 which cannot provide adequate levels. Complete
loss of SMN2 in homozygous SMN1 humans results in no pathogenicity. In fact, the
strongest indicator of SMA severity, classified by age of onset and ability to sit or walk in
I to IV, is the SMN2 copy number which can vary from 2 to 5.(Mailman et al., 2002)
Given the range of SMN2 copy numbers and the amount of SMN protein produced below
a critical threshold, it is not surprising that there is a range of affected patients. There is a
very poor prognosis for type I SMA patients with one or two SMN2 copies; they are
diagnosed within six months of birth, having a 90% mortality rate by age four.(Oskoui,
2007) The less severe type II SMA patients usually have 2-3 copies of SMN2; the disease
onsets before age three, they typically die in the mid-20s, and have difficulty walking
unaided.(Finkel et al., 2014) More mild types III and IV are diagnosed past age three up
until the mid-20’s and can see limited mobility to nearly normal functions and usually
expect a full life.(Punnoose, 2011; Darras, 2015) A small number, 3-5%, of SMA patients
of all types carry missense mutations in SMN1 rather than total deletion or
conversion.(Campbell et al., 1997) These mutations can generally be found clustered in
three regions: those affecting oligomerization in a region termed YG-Box, those affecting
recognition of symmetrically dimethylated arginine residues in the Tudor domain, and
those affecting binding of SMN to Gemin2 in the Gemin2 binding domain (Figure
1.3.1).(Burghes and Beattie, 2009) Given the progression of SMA as a motor neuronal
disease it might be surprising that SMN is ubiquitously expressed, and significant attention
has been given to the matter, and its functions in neuro-muscular cells.(Cauchi, 2010)
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Almost concurrently with the discovery of the SMA causing gene SMN, an antibody was
being raised to the same protein discovered in hnRNP binding assays in the Dreyfuss
Laboratory.(Liu et al., 1997) Due to much of the work on the molecular mechanisms of
the SMN complex in snRNP assembly was highlighted in the proceeding subchapter on
the SMN complex, here I will discuss the relationship between snRNP assembly and
disease. The SMN complex and in particular SMN have had many implications in a host
of RNP functions and regulation from transcription to splicing to trafficking in the nucleus,
which makes trying to nail down why SMA is primarily a motorneuronal disease very
difficult.(Gertz et al., 2012; Yamazaki et al., 2012) However, of the many functions
assigned to SMN, only the assembly of spliceosomal snRNP and U7 can be measured and
have strong correlation to disease.(Gabanella et al., 2007)

Using a mouse model and

cellular knockdowns engineered to replicate disease phenotype, there are clear changes in
snRNP levels that strongly correlate with SMN protein levels.(Zhang et al., 2013) The
reduced assembly capabilities of SMA models has also been seen in patient derived
lymphoblasts as well as primary fibroblasts.(Boulisfane et al., 2011; Zhang et al., 2008)
Importantly and perhaps shedding light on why motorneurons are affected first, tissue
specific snRNP repertoire showed a broad range of changes with spinal cells having some
of the greatest reductions. These snRNP changes and reductions in microsectioned SMA
model mouse spinal cord show loss of proper mRNA regulation for several genes crucial
for neuro-muscular junction formation and maintenance.(Zhang et al., 2013)
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Although snRNP assembly is the best characterized function of SMN, there are a host of
non-snRNP RNA binding proteins that SMN interacts with, which are involved in many
processes any of which could be a contributing factor in SMA pathology. Several of these
SMN interacting proteins including HuD, KSRP, FMRP, and IMP1 all of which are
involved in axonal transport of mRNAs.(Fallini et al., 2011; Fallini et al., 2014; Tadesse et
al., 2008) Indeed, SMN itself localizes along the edge of axons where it may be associating
with important mRNAs, the most important of which is b actin, which is found to be
consistently down regulated in SMA models and SMN knockdowns in the axon of motor
neurons.(Glinka et al., 2010; Wilfried Rossoll et al., 2003) While attractive in explaining
why formation of the anterior horn of the motor neuron is deficient with SMN knockdown,
knockdown of b actin separate from SMA shows no neuromuscular connection
deficiencies and thus is losing favor.(Cheever et al., 2011) SMN also interacts with a host
of other proteins known to be involved in neurodegeneration such as TDP-43 and FUS
involved in amyotrophic lateral sclerosis (ALS), and genotyping shows lower levels of
SMN correlating with increased severity of that disease.(Gertz et al., 2012; Yamazaki et
al., 2012; ZHOU HuaLin MANGELSDORF Marie LIU JiangHong ZHU Li WU Jane Y,
2014) All of these lend credence to the thought that while SMA most likely is primarily
due to snRNP deficiencies, there are most likely other contributing factors due to SMN’s
importance in so much of RNA processing and regulation.
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Figure 1.3.1 Coding mRNA architecture of SMN and SMA causing mutations
Shown are most common mRNAs coding regions from SMN1 and SMN2. SMN2 is
identical in blue regions exons 1-6 and lacks exon 7 resulting in premature termination and
incorporation of sequence EMLA and protein SMN∆7. Shown above SMN1 are the defined
domains of SMN and below are disease causing mutations found in patients listed with
amino acid changes and positions. Mutations indicated have SMA phenyotype shown
above increasingly filling in a square, least severe type III (yellow), type II (orange) and
type I (red) as indicated in the legend. Mutational hotspots are found primary in tudor and
YG-box domains.

30

SMN2

31

1
2a
Tudor

2b
3

3

4

4

P245L
L260S/G
S262G/I
M263R/T
S266P
Y272C
H273R
T274I
G275S
G279C/V

2b

A188S

2a

W92G
V94G
G95R
A111G
I116F
Y130C/H
E134K
Q136E

1
D44V

SMN1
D30N

A2G
Gemin2 BD
Poly Proline

5

5

YG-Box

6

6

7

SMN

YG-Box

SMN∆7

EMLA
SMA Type

I
II
III

Interaction of the SMN Complex Components
Sm5 Dependent association of Gemin2 with SMN
SMN and the SMN complex have essential roles in RNP assembly and regulation, as well
as fundamental importance in human disease. It is therefore critical to understand how the
core of the SMN complex works, specifically in snRNP assembly. In trying to understand
SMN complex mediated snRNP assembly, much work has been done with the large
number of often poorly behaving SMN complex proteins from human, with significant
gaps in knowledge still remaining.(Cauchi, 2010) Shortly after the initial discovery of
SMN, its first unique binding partner was identified and fittingly named SMN interacting
protein 1. Despite its early discovery, little was known about this interacting protein, which
would later be renamed Gemin2. Lack of detailed knowledge about Gemin2 is highlight
by the longstanding thought that: “All of the proteins of the SMN complex except Gemin2
directly bind Sm proteins”, which was later found to be nearly the opposite.(Battle et al.,
2006) It was therefore surprising when Gemin2 was shown to be the key interactor for Sm
proteins D1/D2 and F/E/G (Sm5). In Gemin2, most of the Sm5 binding surface is made of
a long, extended loop and helix which is found very far from the core, this loop and helix
of Gemin2 I will term amino terminal domain (NTD). The remained of the protein contacts
SMN through a distal surface on its carboxy terminal domain (CTD). Given the history of
Gemin2 it should not be surprising that its association with SMN was also taken for granted
and assumed to be an unbreakable bond.(Sarachan et al., 2012) Despite great advances
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and effort, both the core particle of the complex, SMN-Gemin2, and how they function are
still relatively poorly understood. Here I will show that Gemin2 association with SMN is
highly regulated; its binding to SMN is in fact triggered by binding to Sm5.
In trying to interrogate the basic functions of snRNP assembly, I initially chose to use the
simplest complexes from model organisms to accomplish this. The SMN and Gemin2
proteins from S. pombe are an attractive target as they are among the smallest SMN and
Gemin2 in size removing some elements which are likely regulated by other Gemins, the
only components of the SMN complex found in that organism, and S. pombe is amenable
to genetic manipulation. While the human system has been the focus of most studies both
within and outside of our laboratory and the ultimate goal for trying to understand SMA,
any findings using the S. pombe system should translate to the human system, given the
high degree of conservation.
After successfully cloning and purifying SMN, Gemin2, and all seven Sm proteins from S.
pombe, I sought to verify their biochemistry by performing a simple interaction study
through a pull-down experiment, expecting interaction. Using the unique maltose binding
protein (MBP) tag on SMN to pull down the complex, I expected to see equimolar amounts
of SMN, Gemin2 and Sm5 (Sm F/E/G and D1/D2), with Gemin2 bridging SMN and Sm5
due to known stoichiometry. To my great surprise Gemin2 associated only weakly with
SMN alone (lane 3); however, addition of Sm5 greatly increased association (lanes 7 & 8)
(Figure 2.1.1). As expected, SMN had no interactions with Sm proteins for two reasons:
first, in E. coli expression they would remain unmethylated, which is a requirement for
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SMN-Sm interaction; and second, S. pombe SMN has no apparent Tudor domain or other
domain known to interact with Sm proteins. After repeating this experiment many more
times to be absolutely certain of these results which have thus far not been reported with
similar experiments having been published on many occasions, I wanted to see if this was
also true in a human system.
With the wealth of data we have on the human SMN-Gemin2 system, I was able to find
examples of earlier unexplained results showing this variance in binding within
unpublished data in the lab. Many experiments showed similar Sm5 dependent binding of
Gemin2 to SMN; however, a few did not show preference for Sm5. Common to most of
the experiments that lacked Sm5 specificity was a glutathione S-transferase (GST) tag on
Gemin2. GST has the side effect of causing dimerization of anything it is fused to, whereas
we have always found Gemin2 to be monomeric in solution. A likely result of forcing
Gemin2 into dimer is that binding to oligomeric SMN would have a much stronger
interaction due to increased valency, not to mention that Gemin2 NTD might be forced into
a non-native conformation with such a large tag. To try and establish whether or not the
Sm5 dependent binding of Gemin2 was also found in human, I cloned human Gemin2
using only a His6 tag and replicated the concentrations, buffers and procedures as I had
with the S. pombe pull-down. The unexpected S. pombe system results were quickly
reproduced with the use of human proteins and consistent with the Sm5 dependent binding
result, showing a strong SMN-Gemin2 interaction with Sm5 and a weakened one without
(Figure 2.1.2). Again, the Sm proteins were produced in E. coli and would not have
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received methylation on their RG tails and thus are less likely to directly interact with SMN
or bridge SMN-Gemin2.
Looking at the available structures of full-length Gemin2, it is immediately clear that a
large surface area on Gemin2 contacts Sm5 through a winding amino-terminal domain
(NTD). This domain is crucial for Sm5 recognition and must adopt a different
conformation in their absence. In further trying to dissect this novel regulation, I chose to
remove the NTD of Gemin2. My initial hypothesis was that an NTD-lacking Gemin2,
despite having a canonical SMN binding domain, would be unable to bind SMN due to the
loss of Sm5 binding capablity. While Gemin2 carboxy-terminal domain (CTD) did lose
Sm5 regulation of SMN interaction, surprisingly it did not weaken interaction but instead
showed an increase in SMN binding. These results indicated that the NTD must also be an
element of auto-inhibition, in addition to binding Sm5 (Figure 2.1.1 lanes 9-13).
Examining data on post-translational modifications of Gemin2 in S. pombe yielded an
interesting possibility for regulation of SMN-Gemin2 or Gemin2 NTD-CTD interactions.
Specifically, serine 118 is phosphorylated during mitosis when the nucleus mixes with the
cytoplasm, which would expose Gemin2 to all of the mature snRNPs normally found only
in the nucleus.(Koch et al., 2011) By its nature Gemin2, must have some, albeit weaker,
affinity for the Sm proteins in these snRNPs and and thus could potentially bring them to
SMN resulting in potentially deleterious effects such as stalling the SMN complex at the
final snRNP assembly step, or deconstruction of these mature snRNPs. The site of
modification, serine 118 sits just above the SMN binding pocket on Gemin2 and could
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easily be in the path of either SMN or Gemin2’s NTD binding, and thus heavily influence
which of them is binding at that critical juncture. To see what effect this had on SMN
binding to Gemin2 I made a phosphomimic S118D. This mutant behaved exceptionally
well during purification and resulted in both high yields and low contamination. When it
was tested for Sm5 dependent binding to SMN it showed reduced association in all cases
(Figure 2.1.3). These results further support that SMN and Gemin2 interactions are
regulated by Sm5. It must be beneficial to S. pombe to lock up or otherwise stop Gemin2
from binding to SMN when the nuclear envelope is dissolved. While this phosphorylation,
and indeed serine 118, are not conserved in higher eukaryotes, it is possible that something
else is modified at another location, perhaps by one of the emergent Gemins, in order to
prevent the deleterious effects of mature snRNP association.
Direct interaction through NTD and CTD could not be found with pull-downs, which is
not unexpected as it should be a relatively weak interaction when tested intramolecularly
compared to the much stronger bond when tethered. Difficulty in seeing a direct interaction
this way is compounded by the non-specific binding of NTD both for free MBP on beads
used as a control as well as the many contaminants it brings along during the purification
process. Pulldowns with full-length Gemin2, CTD, and phosphomimetic mutations; FRET;
and modeling strongly suggest that Gemin2’s NTD auto inhibits binding to SMN, is
designed to be regulated and functions as a sensor for Sm proteins. Although the precise
mechanism of this interaction, either direct binding of the NTD to the CTD or another
allosteric change, is not clarified by these studies it does open methods to explore this
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interaction and clarify how the NTD acts to stop SMN binding. In order to assess whether
the NTD and SMN binding pocket are in close proximity, I looked at using a distance
dependent probe in the form of two fluorophores with overlapping spectra with a technique
called Förster resonance energy transfer (FRET).(Schuler et al., 2005)
To try and find out where Gemin2’s NTD is in relation to the SMN binding pocket, I aimed
to attach a pair of fluorophores to both of those locations. I chose to use cyanine 5 (Cy5)
and FAM (Fluorescein amidite) due to lower spectral overlap and bleed through of nonFRET signals.(Martí et al., 2007; Richards et al., 2010; Schneider et al., 2010b) To attach
the Cy5, I used a maleamide conjugate and reacted it with wild-type protein. I had found
through cysteine 141 mutant, and cysteines 178 and 180 double-mutant that only cysteine
141 showed much activity with Ellman’s reagent (DTNB), which fluoresces upon reaction
with solvent exposed sulfhydryls, and thus wild-type protein could be used. I initially
attempted to place an internal cysteine in the NTD so I could incorporate one of the
fluorophores there with maleamide. However, after trying three different cysteine
mutations in the NTD, I found none of them to express well or have pure enough yields for
use in FRET. I then looked to attach the fluorophore to the amine on the very amino
terminus. Having previously found Gemin2 36-235 to behave like wild-type for Sm5
dependent binding to SMN (data not shown), I used this truncation as the fluorophore
would be closer to the site of my interest, the hydrophobic helix which contacts SmE and
F. I first labeled with NHS-FAM (NHS is moiety reactive toward primary amines) to attach
FAM to the amino-terminus specifically by reacting in acidic conditions to ensure partial
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deprotonation of only the amino-terminus. After removing unreacted HNS-FAM from the
protein, I measured FAM using OD495 and protein concentration using OD280 correcting
for any FAM signal at OD280. These two concentrations were nearly identical, with a 19:20
FAM to protein ratio, and I assumed the efficiency meant only one FAM per peptide
labeled specifically at the amino terminus, opposed to a mixture of species coincidentally
averaging a one to one ratio, the results of several states are consistent with this assumption.
Some of the single labeled protein was saved both for baseline corrections and to record
FAM signal without a FRET donor, while the majority was then labeled at C141 with
Maleamide-Cy5. After correcting for both FAM and Cy5 (negligible) OD280 of this sample,
I found that after considerable optimization only about 20% of molecules had a Cy5
incorporated. This poor labeling could be corrected by assuming that only one fifth of
molecules were capable of FRETing. This double-labeled protein was now ready for FRET
experimentation to test efficiency of FRET in Gemin2 with and without Sm protein and
SMN.
To see how close the fluorophore pairs are FRET efficiency is measured, with higher
efficiency resulting from closer probes. FRET efficiency is measured most easily as a
decrease in the signal of the donor fluorophore over the signal of the donor without an
acceptor fluorophore. There is very high FRET efficiency in double labeled Gemin2
without substrates, consistent with a closed state where the NTD is nestled in or near the
SMN binding pocket. The efficiency was measured at 0.99 ± 0.06. Unfortunately, as
efficiency is dependent on the distance by the sixth power, values near 0 or 1 yield
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unprecise distances; however, this value demonstrates that these are close to one another
as the maximum range is very small (Figure 2.1.8). Addition of SMN Gemin2 binding
domain (Ge2BD) does not change the efficiency (1.02 ± 0.06), which is again consistent
with it not binding or displacing Gemin2 NTD. However, there is a dramatic change in
FRET efficiency upon addition of Sm5 to 0.44 ± 0.09, consistent with opening and
displacement of the NTD from the CTD.(Ye et al., 2012) Interestingly, the addition of
both Sm5 and SMN Ge2BD further decreases FRET efficiency to 0.25 ± 0.21, this value
again starting to fall outside of the range for useful distance measurement although clearly
a very large change in location. The large error is further due to difficulties in precise
measurement nearing the extremes. The added reduction in FRET efficiency with the
addition of all substrates suggests that while Sm5 displaces most of the NTD, it is still able
to breath and flex; switching between binding to Sm5 and being free to potentially rebind
the CTD, and is then locked into place with the stabilization energy of Gemin2 binding to
SMN Ge2BD.
While many of these values for FRET efficiency are outside of the useful range for distance
measurement, and many more experimental controls and measurements would need get
accurate distances, I still chose to get a rough measurement. Getting these rough
measurements required establishing two things. First, the distance at which FRET
efficiency is 0.50, R0, needed to be found and second, I needed to be sure that any change
in efficiency was due only to a change in distance rather than orientation or electronic
environment. Using literature values for the spectral overlap constant (J) of 1.34 x 10-13
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cm6 mol-1 and correcting for buffer environment (which turned out to be negligible), I came
up with an R0 of 61.3 Å.(Martí et al., 2007) This value is larger than the average FRET
pair, but still within the normal range.(Johnson and Spence, 2010) While I cannot control
for electronic contribution due to Gemin2’s conformation changes, I made sure all states
had identical buffers and total protein amounts by supplementing with BSA to exclude
those effects on FRET efficiency as much as possible. With this value for R0 I was able to
come up with some rough estimates of distance for each of the four states. I find that
Gemin2 alone has a distance between acceptor and donor fluorophores of between 0-34 Å,
which is very broad given that the nature of FRET accuracy is a function of distance to the
sixth power and therefore best at an efficiency of 0.50. This limited distance measurement
is still under the ~40 Å that would be seen if it were located on the distal face of Gemin2.
Gemin2 with SMN Ge2BD had a very similar efficiency and thus would have also been
under 34 Å. Upon the addition of a slight excess (1.2 x) Sm5 to Gemin2, the distance
between probes jumps to 76 Å. This distance is within expected distance of 55 to 118 Å
when modeled onto the crystal structure accounting for flexibility due to unstructured
amino acids on the N-termius and linker (Figure 2.1.9). The final distance measured for
both Sm5 and SMN Ge2BD is 88 Å, and again nicely matches likely distances seen in a
crystal structure of this complex.
Taken together, data from the pull-downs showing that the NTD of Gemin2 functions in
an autoinhibition of SMN binding, and the close proximity of NTD to the SMN binding
domain (SMN BD) seen with FRET are suggestive of a direct interaction of Gemin2’s
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NTD and CTD. It is particularly interesting that the addition of SMN Ge2BD to Gemin2
with Sm5 further decreases FRET efficiency. The best explanation for this is that Gemin2
is constantly grabbing and releasing, or otherwise more poorly holding onto Sm5 when the
NTD still has a potential site in Gemin2 CTD to bind to. Only when SMN is bound to
Gemin2’s CTD does the NTD’s grip on Sm5 become indomitable. While these data both
point to the two domains of Gemin2 interacting without Sm5, the rationale for how this
occurs is still missing, but there are a few clues. The interaction of Gemin2 with SMN
occurs largely through hydrophobic contacts, and the NTD of Gemin2 contains several
hydrophobic residues which aid in the binding of Sm5. Both SMN’s Ge2BD and Gemin2
NTD are at some points aliphatic helices and it is conceivable that they could interchange.
Furthermore, it seemed highly likely that, in the absence of substrates, Gemin2 would try
and prevent the exposure of two hydrophobic regions by collapsing them onto each other.
To assess the likelihood of this, we chose to model interactions with separate Gemin2 NTD
and Gemin2 CTD peptides.
In trying to model how Gemin2’s NTD can auto-inhibit its CTD from binding to SMN, I
needed to establish which regions of the NTD to model. Ultimately, I chose to use amino
acids 48-68 for several reasons. First, this region is the most highly conserved part of the
NTD, and indeed of the whole protein. Second, through truncation experiments I had found
that the auto inhibition occurred between amino acids 36 and 80. Third, in order to
potentially reach all surfaces on the CTD, a linker of more than 20 amino acids is required.
Finally, the part of SMN responsible for binding Gemin2 is only about 21 amino acids, and
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thus all tested peptides should be the same length to keep the potential total energies the
same per residue and to eliminate the possibility that size leads to too much steric
interference seen in one model, but not another. To generate a model, I needed to use a
known structure and thus chose to use human sequences for Gemin2 and amino acid 81280 from 3S6N as the basis for the CTD.
In looking for programs capable of docking or molecular modeling I chose to use CABSdock as it had several advantages. It was easy for me to access and run on a cloud based
server. It was optimized for binding peptides (>30 aa) to protein (>500 aa) and is not
specifically designed for hydrophobic or hydrophilic interactions, but is general; therefore,
it should not be biased toward our hypothesized hydrophobic interaction mode. It allowed
for both large reorientation and flexibility in the docking peptide and some motion in the
larger CTD fragment. It modeled thousands of trajectories and automatically assigned,
clustered and classified them. Using CABS-dock, the results of the best ten models would
be put into coordinates so we could carefully look at them.
Testing potential binding sites of Gemin2’s NTD using CABS-dock, we found it docked
in a position incompatible with full-length Gemin2-SMN binding in 9 of 10 generated
models; that is to say, it bound somewhere within Gemin2’s SMN binding domain (Table
2.1.1). As a positive control, SMN’s Ge2BD and Gemin2’s CTD correctly located to
SMN’s binding site in 8 of 10 models. Importantly, a peptide from Sm D1’s CTD found in
the prior experimental conditions did not bind to this interface in 7 of 10 models.
Additionally, docking studies were performed using an NMR structure for Gemin2 CTD
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(PDB: 2LEH) and for another X-ray crystallography structure of fly Gemin2 CTD, with
fly NTD (PDB: 4V98) both showing binding of NTD to CTD in the SMN binding pocket.
These three results suggested that the Gemin2 CTD surface for SMN binding is the same
location where Gemin2 NTD is predicted to bind with some specificity. These simulations
suggest that in its native state, unbound by Sm proteins or SMN, Gemin2’s NTD covers up
its SMN binding site in the CTD, which neutralizes two highly hydrophobic regions of
Gemin2 on its NTD and CTD (Figure 2.1.6 and 2.1.7).
The docking of the NTD to the CTD is perhaps not surprising given that these regions are
among the most concentrated in terms of hydrophobic residues. Careful examination of
available crystal structures of Gemin2 show that SMN’s Gemin2BD binds Gemin2’s CTD
at a highly hydrophobic and shallow pocket that would be solvent exposed otherwise
(Figure 2.1.4). It would be expected that unbound Gemin2 would have to find a way to
mitigate this hydrophobic surface or become bound to chaperones, aggregated, or unfolded.
Both of these regions are highly conserved, and through necessity or design, the easiest
way to block the exposed hydrophobic surfaces they present is to put them in direct contact
with one another, something predicted by docking models.
To try and assess where and how much hydrophobicity would be exposed upon Gemin2’s
CTD without its own NTD or SMN, I determined the hydrophobic potential of each
residue. I was able to generate a score for the hydrophobicity of each amino acid in Gemin2
and map that onto the available crystal structure (Figure 2.1.4 and 2.1.5) using the partial
diffusion coefficient into oil or water for each amino acid as a basis for hydrophobicity
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weighted by nearby residues. These scores ranged from 0.882 (I262 buried in the core) to
–1.274 (R78 unseen loop between NTD and CTD) with positive numbers having
hydrophobic preference and negative having hydrophilic preference. For reference, amino
acids vary from isoleucine, the most hydrophobic, at 1.38 to arginine, the least, at -2.53,
while threonine is the closest to neutral at -0.05.(Eisenberg et al., 1984) I chose to weight
the hydrophobicity by nearest neighbor in primary sequence to establish a smoother
transition and account for environment. Using the primary rather than tertiary sequence
allowed for an equal potential score for each amino acid and was less arbitrary. 25% of the
hydrophobic contribution came from the base amino acid and then 18.75, 12.5 and 6.25 %
from each one next in sequence. These scores were taken to ± 4 amino acids to cover the
interactions in an alpha helix which comprises most of the structure of Gemin2. Amino
acids closer than four from either termini would be uncounted, but they did not appear in
3S6N and thus would not affect the results.
Mapping the hydrophobicity onto each amino acid and then weighting to the total surface
area exposed would allow me to see the areas of exposure and how this changed when
residues from other substrates potentially occluded these regions. This residue
hydrophobicity coupled with solvent exposed surface area (SASA) showed a large increase
in net exposed hydrophobicity in Gemin2 CTD’s SMN binding pocket (within 5Å of SMN)
without the SMN peptide. This region is highly hydrophobic and contains 27% of the total
hydrophobicity within 14% of the SASA of Gemin2 CTD. Conversely, Gemin2 CTD as a
whole has an expected negative surface hydrophobicity at -0.16 when normalized to each
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amino acid; this is very near to a poly-serine (-0.18). The SMN binding pocket itself is
hydrophobic at +0.17 per residue, somewhere in between proline (+0.12) and tyrosine
(+0.26). I rationalized that this very hydrophobic region would be unstable and should be
covered; in fact, the only other region to display so much hydrophobicity is Gemin2’s NTD
(22-31 & 47-69) which would otherwise bind Sm5 at -0.04 per residue without Sm5
and -0.11 with. According to these models, Gemin2 N-peptide binding to the CTD would
both block SMN Gemin2BD binding and strongly reduce the hydrophobic SASA. Gemin2
N-peptide blocked between 52-64% as an upper estimate and 17-28% as a lower of SMN
binding. Using this method, SMN covers 100% in the upper estimate and only 31% in the
lower of its own binding. Hydrophobicity changed upon binding by 15-22% on the CTD,
consistent with an SMN (peptide) reduction of 18%, and return to negative (i.e.
hydrophilic) hydrophobic SASA of the hydrophobic cleft and Gemin2 CTD (Table 2.1.1).
The ranges given represent minimum and a maximum overlap SASA between SMN and
docked peptides based on assumptions of divergence or convergence and elaborated on in
the methods. The overlap between the models and SMN crystal structures must be
somewhere between those extremes, but logically it should be closer to the maximal
percentage blocked, as residues SASA are not independent of one another and some of the
SASA might be inaccessible all peptides.
These exposed hydrophobic regions likely cause degradation, unwanted interaction or
aggregation. Exposed hydrophobic regions are seen as a root cause in several
neurodegenerative diseases, and in both b thalassemia and sickle cell anemia they are at
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least a partial result of dysregulation of exposed hydrophobicity in α-globin(Feng et al.,
2004) . In hemoglobin, both α-globin and b-globin are expressed and function in a 2:2 ratio.
However, if there is too much α-globin a chaperone protein, AHSP, binds to prevent
exposure of this hydrophobic region, which would otherwise be toxic. The per residue
hydrophobicity of α-globin is +0.07 and chaperone binding reduces this to +0.04, a much
smaller change than seen in Gemin2 self-interactions and SMN/Sm5 binding
(PBD:1Z8E).(Feng et al., 2004; Mackay et al., 2005) This process is very analogous to
what occurs with SMN and Gemin2, where there is sufficient SMN to cover exposed
hydrophobicity in Gemin2 with Sm5 bound. If Gemin2 is in excess to SMN, Gemin2 can
potentially be toxic, and while there is no dedicated Gemin2 chaperone such as AHSP I
would not expect one for the rare cases like SMA when it would be.
Taken together all of these data strongly suggest that Gemin2 is independent of, or weakly
associated with, SMN in the absence of Sm5. In this free state, Gemin2’s NTD nestles in
or near the SMN binding pocket greatly reducing SMN-Gemin2 interaction mediated by
hydrophobic interactions on both surfaces. The binding of Sm5 kicks out the NTD and
exposes Gemin2’s SMN binding pocket. There are possible alternative conclusions and
concerns with the data. I have made my best effort in ruling them out and am satisfied that
most are not likely, but for completeness will present several here: (1) These interaction
variations are dependent on use of mild detergents, and while all proteins contaminate free
and with the exception of SMN being a tetramer, are monomeric, the possibility exists that
loss of Gemin2 binding could be due to an unnatural misfolding which is rectified by the
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addition of Sm5; this misfolding must also be dependent on the NTD. (2) There is another
allosteric change on a different surface requiring the removal or pulling of the NTD to
reshape Gemin2 and affect the SMN binding pocket. The simplest model, and the one I
have chosen to present, is one where the structure of the CTD is static and the NTD changes
its folding pattern in the absence of Sm5. Another mode of allosteric regulation is entirely
possible and might fit within the data as presented here, although all data agree with my
simple model. (3) FRET efficiency changes might be due to a change in the orientation or
degrees of freedom of one or both probes such that they spend more time aligned in Sm5
free states than without. (4) CABSdock will find a binding event no matter how bad and
clustering for some peptides might be more dependent on having structure. For example,
both NTD and SMN Ge2BD are helical whereas SmD3 tail is likely unstructured. (5)
Approximations for hydrophobicity might be inaccurate and they fail to fully account for
all environmental changes, although all species show the same pattern, and changes in
exposed surface are nearly the same for observed species both with and without using
weighted hydrophobicity for neighbors. Another method of measuring hydrophobicity not
explored might yield different results.
Exciting data, though pull-downs, FRET, and molecular docking experiments, paint a more
detailed picture of Gemin2 and its new interesting role in bringing Sm5 to the SMN
complex and potential to signal that process. The NTD clearly has an effect on binding to
SMN which is relieved by binding Sm5. This interaction difference is conserved from S.
pombe to man and can also be partially regulated through post-translational modification.
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Without Sm5 the NTD is very close to the CTD’s SMN binding pocket as seen by FRET.
Further modeling software predicts an NTD binding surface on the CTD which is
incompatible with SMN binding. Binding of the NTD to the CTD eliminates hydrophobic
surfaces on both domains which can potentially lead to toxicity or disease, and will in fact
be demonstrated in the following chapter. This new state is the foundation on which a
detailed vison of snRNP assembly will be built and expanded upon in the following
sections.
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Figure 2.1.1 Gemin2 requires Sm5 binding to NTD for SMN interaction
Gemin2 shows a weak affinity for SMN without Sm5 (SmD1/D2 and SmF/E/G) (lanes 36) then becomes a tighter SMN binder in their presence (lanes 7&8) from S. pombe
proteins. The need for Sm5 binding to Gemin2 in order for SMN binding is relieved when
the 87 amino acids at the N-terminus are removed (Gemin2 CTD) (lanes 9-13). Interactions
are demonstrated by using MBP-SMN bound to amylose beads, and show specificity for
SMN as indicated by no binding to MBP control (lanes 1 and 2). The total lanes show 10%
of the recombinant proteins for the binding and the gels are visualized by silver staining.
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Figure 2.1.2 Conserved Sm5 dependent binding of Gemin2 to SMN
Gemin2 shows a weak affinity for SMN without Sm5 using human proteins. Upon the
addition of Sm5 to Gemin2 binding to SMN is greatly strengthened. Interactions are
demonstrated by using MBP-SMN on amylose beads as bait. The total lanes show 10% of
the recombinant proteins for the binding and the gels are visualized by silver staining.
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Figure 2.1.3 Phosphorylation regulates SMN-Gemin2 interaction
In S. pombe phosphorylation limits Gemin2 binding to SMN even with Sm5. Wild type
Gemin2 shows a weak affinity for SMN without SmD1/D2 or SmF/E/G and especially
Sm5 (lane 1) then becomes a tight binder in their presence (lanes 2, 3, and 4 respectively).
Phosphomimitic S11D substantially reduces SMN binding as compared to wild-type in all
cases (lanes 5-8). The need for Sm5 to bind Gemin2 in order for SMN interaction is
removed when the N-terminus is truncated (Gemin2 CTD) (lanes 9-12). Interactions are
demonstrated by using MBP-SMN from on amylose beads. The total lanes show 10% of
the recombinant proteins for the binding and the gels are visualized by silver staining.
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Figure 2.1.4 Model surface hydrophobicity of Gemin2
Gemin2 is shown as a surface model with the hydrophobic residues colored yellow
according to their relative hydrophobicity with white having no hydrophobicity, and the
most hydrophobic as fully yellow. SMN and SmD1/D2 & F/E/G are shown in blue as
secondary structure with a partially transparent surface. Hydrophobicity drawn onto 3S6N
and shown in three different orientations. If uncovered these regions should lead to
deleterious effects.
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Figure 2.1.5 Conserved hydrophobicity of Gemin2
A multiple sequence alignment of Gemin2’s from human, mouse, chicken, frog, fly, worm,
and fission yeast along with Brr1 from budding yeast are shown as representative
alignments from a larger pool of 178 species, generated using T-coffee espresso. Colored
in increasingly yellow on each residue is the hydrophobicity of it weighted by its local
environment for each species. Shown below are residues within 5 Å of SMN (blue),
SmF/E/G (green) and/or SmD1/D2 (red) seen in 3S6N. If uncovered these regions should
lead to deleterious effects.
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Figure 2.1.6 NTD Peptide of Gemin2 Docked onto CTD in Most Favorable Position
(A) Gemin2 is shown as a surface model with the hydrophobic residues colored yellow
according to their relative hydrophobicity with white having no hydrophobicity. SMN and
Sm5 are shown in blue cartoon with a semi-transparent surface in their binding in 3S6N
and observed binding of SMN to the hydrophobic cleft of Gemin2 CTD. (B) Top ranked
predicted docking site for N-terminal sequence of Gemin2 to the CTD. (C) Top ranked
predicted docking sites for SMN Ge2BD to Gemin2 CTD. Models are shown in blue sticks
with transparent surface. Docking models are shown at 150% scale compared to actual
structure.
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Figure 2.1.7 Top models for Gemin2 NTD, SMN Ge2BD, and SmD1 RG tail
(A) Top ten ranked models of Gemin2 N-terminal peptide binding to CTD. (B) Top ten
ranked models of SMN Ge2BD peptide binding to CTD as positive control. (C) Top ten
ranked models of SmD1 C-terminal RG peptide binding to CTD as a negative control.
Model peptides are shown in light blue. Gemin2 is shown as a surface model with the
hydrophobic residues colored yellow according to their relative hydrophobicity with white
having no hydrophobicity. Models show hydrophobic pocket facing forward and rotation
for binding on the other side (A and B) or indication of rotation for 7 of 10 SmD1 RG
docking (C).

61

A
Gemin2 N-Peptide Docking
Model 1

Model 2

Model 3

Model 4

Model 6

Model 7

Model 8

Model 9

Model 5

Model 10

180˚

B
Gemin2 SMN-Peptide Docking
Model 1

Model 2

Model 3

Model 4

Model 5

180˚

Model 6

Model 7

Model 8

Model 9

Model 10

180˚

C
Gemin2 SmD1 RG Docking
Model 1

Model 2

180˚

Model 6

180˚

Model 7

180˚

62

Model 3

Model 5

Model 9

Model 10

180˚

Model 8

180˚

Model 4

180˚

180˚

Figure 2.1.8 FRET efficiency of NTD and CTD labeled Gemin2 with Sm5 and SMN
Gemin2 labeled on its amino terminus with a donor fluorophore has high FRET efficiency
with an acceptor located near the SMN binding pocket without proteins (green) or with
only SMN peptide (blue), the efficiency decreases dramatically when Sm5 is added (red),
and locks to a slightly lower efficiency with both SMN and Sm5 (purple). Based upon
3S6N an open, fully extended Gemin2 would have light grey levels like Sm5 +/- SMN, and
if the NTD were docked only on the SMN binding pocket side of the CTD efficiency would
look like dark grey, as see with Gemin2 alone and no effect of SMN.
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Figure 2.1.9 Gemin2 structure showing positions of FRET pairs Cy5 and FAM
FRET pairs Cy5 (red) and FAM (green) are shown bound to Gemin2 (white) from 3S6N
in likely positions on the CTD and a portion of the sculpted NTD (dark grey) respectively.
Gemin2 is shown in white (actual) and modeled (dark grey) surfaces, with SMN (blue) and
Sm5 (yellow) displayed as secondary structure. Shown in decreasing red circles is the
expected FRET efficiency for each distance based on an R0 of 63 Å, and the expected
values. The model is then also rotated 90 in an additional view.
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Table 2.1.1 Surface exposed hydrophobicity for all Gemin2 docking models
For each model of NTD binding to CTD as well as for SMN and SmD1/D2 the change in
surface area, and hydrophobicity was calculated, a ratio of change in hydrophobicity to
surface area is represented as the economy of hydrophobic binding, and SMN blocked
regions. The economy of hydrophobic binding indicates if the peptide binds preferentially
to hydrophobic regions (values >1.0) or hydrophilic (values <1.0). Common regions
blocked by SMN and models is presented as both a maximum and minimum overlap further
explained in the methods.
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Structure
SMN
SmD1/D2
Model 1
Model 2
Model 3
Model 4
Model 5
Model 6
Model 7
Model 8
Model 9
Model 10
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Δ Surface
Area

Δ Hydrophobicity

Economy
(hydro/SASA)

-7.6%
-11.7%
-8.7%
-8.1%
-9.6%
-8.8%
-10.5%
-7.7%
-9.9%
-9.6%
-10.5%
-5.3%

-18.0%
-7.9%
-15.6%
-16.6%
-21.7%
-21.0%
-17.7%
-17.9%
-22.5%
-15.2%
-15.5%
-1.3%

2.35
0.67
1.78
2.06
2.27
2.39
1.69
2.32
2.26
1.58
1.48
0.25

SMN Blocked
Max

Min

100%
0%
52%
52%
58%
53%
64%
52%
62%
59%
60%
0%

31%
0%
23%
27%
23%
22%
26%
17%
27%
27%
28%
0%

SMN complex oligomerization and Gemin8 induced polymerization
SMN and the SMN complex have long been known to form heterologous, mega-Dalton
structures in cells mediated by SMN’s YG box. The precise nature of how many SMN
protomers there are, how larger structures are controlled in cells, and what the functions of
such structures are remained unknown. Early in my work, I sought to utilize the simplest
SMN, that from S. pombe, to try and understand some of these questions in a more
controlled system. Past studies have shown that, on a sucrose gradient, S. pombe SMN
expressed in rabbit reticulocyte lysate was a much smaller tighter peak, indicative of a
single homogenous complex.(Paushkin et al., 2000) I chose to express S. pombe SMN in
E. coli for ease of expression and purification and not to perturb the native organism with
excess protein which might lead to toxic side effects, but initially nearly all the expressed
protein was found in inclusion bodies or otherwise precipitated very early in purification,
an issue common to SMNs we have studied in isolation. These problems were overcome
by using a maltose binding protein (MBP) tag for both solubility and expression, as well
as to serve as a unique purification tag. This MBP-fused SMN was able to weakly bind
Gemin2, and through Gemin2 Sm5 could be bound and thus subsequently be added to the
complex. All states of SMN, with or without Gemin2 and/or Sm5, were very soluble and
stable. Cleavage of MBP from SMN resulted in slow precipitation unless Gemin2 was also
present.
To assess the mass and stoichiometry of SMN and SMN-Gemin2, size-exclusion
chromatography coupled with multi-angle light scattering (SEC-MALS) was performed.
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The mass of MBP-SMN native complexes was calculated to be 250±17 kDa, consistent
with a tetramer (MBP-SMN protomer 61 kDa). Addition of Gemin2 increased the mass of
this complex to 408±17 kDa, resulting in an apparent stoichiometry of 4 SMN: 4 Gemin2
(Figure 2.2.1). Additionally, SMN on a blue native gel showed three distinct bands
corresponding to 2, 3 and 4-mers (Figure 2.2.2). Blue native gels were used, as complexes
were not as stable on traditional native gel types. The stoichiometry was further verified
by the titration of Gemin2 into this system, as both Gemin2 and SMN have only one
binding site for each other. This titration resulted in discrete bands of SMN-Gemin2
corresponding to 2:0, 2:1, and 2:2 for the lowest band. For the middle band 3:0 and 3:1
could be assigned. More Gemin2 binding events could not be seen either due to conversion
to another oligomerization state or simply that it was unresolvable with larger oligomers.
For the highest bands, five states could be detected corresponding to states 4:0-4. This
saturation and number of bands is consistent with a tetramer. While there was no detectable
signal for oligomers containing two or three SMNs in SEC-MALS, their appearance on the
blue native gel is likely a result of the hostile environment of the native gel. MBP fused S.
pombe SMN does not remain oligomeric on standard native gels, and the much harsher
condition of passing such a complex through a gel with Coomassie binding as a charge
carrier

likely

disrupts

the

very

hydrophobic

nature

of

YG-Box

mediated

oligomerization.(Schägger et al., 2006) As a testament to the increased strength of S.
pombe SMN YG-box oligomerization, human SMN completely dissociates on a native
blue gel and has an extremely large and heterogeneous peak on SEC-MALS. Thus these
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results demonstrate that in S. pombe SMN is a tetramer and suggest that in other organisms
it must be at least a tetramer and likely composed of units of tetramer.
Work performed by coworkers Jingqi Duan and Byung Ran So has shown that a peptide
of Gemin8’s amino-terminus binds to SMN’s YG box and either induces larger oligomers,
termed polymers, or locks them into place. The most fundamental of these appears to be a
tetramer and is consistent with the results found in S. pombe. Questions still remained as
to whether or not this was true in both full-length SMN and in a human cell line. To address
this, I grew HeLa cells with RNAi targeting Gemin8 and manufactured provided control
RNAi which has no targets; the cell lysate was applied to a sucrose gradient and
ultracentrifuged. As seen in other results, there was a small reduction in SMN protein when
Gemin8 was knocked down, which is likely due to a potential stabilizing effect of Gemin8
induced oligomerization (Figure 2.2.3).(Carissimi et al., 2006) Perhaps unsurprisingly, the
cytoplasmic SMN and several related components sediment lighter in Gemin8 knockdown.
Addition of Gemin8 N-peptide not only restored SMN complex mass, but shifted it much
higher (Figure 2.2.4). These data are highly suggestive of Gemin8 not only locking SMN
into polymerization, but also controlling the extent of polymerization; it is even indicative
that SMN which is not polymeric might be degraded in an effort to rebalance SMN:Gemin8
ratios to achieve a larger species. Given Gemin8's later evolutionary appearance and the
single tetrameric species of SMN in S. pombe, eukaryotes likely required more and more
concentrated SMN to perform important functions and perhaps become more efficient at
assembling snRNPs cells with much larger and more nuanced introns and splicing.
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Figure 2.2.1 SEC-MALS for S. pombe SMN and complexes
MPB fused SMN and SMN-Gemin2 complexes from S. pombe produce a mass and profile
consistent with t tetramer and tetramer of dimers, respectively. SMN complexes have a
mass of 250±17 kDa with a 61 kDa promoter mass and addition of Gemin2 shifts this mass
by 158 to 408±17 kDa, consistent with and addition of four Gemin2s each being 31 kDa.
Peaks (40, and 32 min) have a largely Gaussian shape with SMN displaying a minor
overlapping peak at 46 min later most likely corresponding to free MBP, demonstrating
stability and purity.
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Figure 2.2.2 Blue Native PAGE of S. pombe SMN with Gemin2 titration
Sizes of MBP fused SMN complexes by blue native page correspond well with di-,tri- and
tetramers (protomer 61 kDa) bolded on the side. Addition of Gemin2 (31 kDa) from subto super-stoichiometric amounts shows a distinct laddering that is labeled on the side for
up to 4 binding events with tetrameric SMN, as indicated on the side. G-250 dye used as a
charge carrier may have disrupted some SMN-SMN interactions leading to species smaller
than a tetramer. Gemin2 can be clearly seen to bind both di- and tetrameric species, while
trimeric does eventually disappear it is not possible to resolve possible Gemin2 binding
events from contaminate bands. Gel visualized by de staining from running G-250
comassie dye.
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Figure 2.2.3 Efficiency of Gemin8 knock-down by RNAi
Western blot analysis for Gemin8 and SMN levels after 48hrs of Gemin8 knockdown by
RNAi in HeLa cells. (A) Gemin8 levels are substantially reduced when treated with
Gemin8 RNAi cocktail to 18-5% of wild-type. (B) Reduction of Gemin8 levels has a
moderate effect on SMN levels with 18% of Gemin8 only 83% of SMN remains and with
under 5% there is a 50% reduction in SMN. Lanes are shown as Gemin8 knockdown +/pep, there is no Gemin8 N-pep in the sample, instead they indicate which sample was use
in the experiment seen in figure 2.2.4.
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Figure 2.2.4 Sedimentation of SMN complexes in HeLa
Ultracentrifugation of HeLa extract with control (A), Gemin8 knockdown (B) or Gemin8
knockdown + add back of Gemin8 N-pep (C) show dramatic shifts in SMN distribution.
(A) The SMN complex with SMN and components Gemin2-8, and unrip (7 & 8 not probed)
show a broad, but very massive distribution with a substantial amount pelleted, it is worth
noting that Gemin6, which together with Gemin7 and unrip are connected to the SMN
complex by Gemin8, has a very light fraction containing two bands and one that is
associated with the heaviest SMNs being slightly smaller. (B) Gemin8 knockdown causes
SMN and components to distribute more toward lighter fractions, Gemin6 association is
also lost as expected. (C) Addition of super-stoichiometric levels of Gemin8 N-pep to
Gemin8 knockdown again shifts SMN complex masses, to fractions even larger than wildtype, yet as expected Gemin6 is not associating due to lack of the CTD of Gemin8. Below
is shown a distribution of Gemin8 N-pep as monitored by FAM fluoresce. Images below
are from western blots scaled to identical levels, faintness of SMN is most likely due to
slight reduction in cell lines with Gemin8 knockdown seen in figure 2.2.3.
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Electron Microscopy of S. pombe SMN-Gemin2-Sm5 complex
With the fundamental importance of SMN and the SMN complex in human disease,
structural information about SMN, and in particular how the YG-box affects
oligomerization of the complex, is critical to achieve. Furthermore, the architecture of the
SMN complex as a whole, especially the location of Sm5, is of fundamental importance
for snRNP assembly. Seeing these structures and knowing the layout of the SMN complex
should aid in explaining why oligomerization is so vital for the SMN complex. These
results will both aid in drug discovery and increase understanding about how RNPs are
assembled and maintained in cells. Given that the SMN complex in S. pombe is more
homogenous in both components, with only SMN and Gemin2, and in oligomerization,
adopting a stable and monodispersed tetrameric structure, this organism is the most
attractive target for determination of a complete structure of the complex. While
crystallization efforts have yet to prove fruitful, S. pombe SMN complex remains an
attractive candidate for electron microscopy (EM) facilitated structural determination due
to its size and simplicity.
To generate a suitable complex for EM, I co-lysed all components of the S. pombe SMN
complex with large excesses of Sm5 and excess Gemin2 compared to SMN. These proteins
were then purified through tandem affinity tags first targeting Gemin2/Sm5, and then
targeting SMN. This was followed by SEC yielding a monodispersed complex of an
apparent mass consistent with at 4:4:4 ratio. Initial application of this complex to EM grids
and negative stain with uranyl acetate showed only very small scattered complexes,
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demonstrating that under these conditions the complex was dissociating. I then worked to
hold the complex together using the GraFix method, optimizing both the concentration of
glutaraldehyde and the glucose gradient as well as ultracentrifugation duration and
speed.(Stark, 2010) To check the crosslinking efficacy, I sampled fractions and loaded
them onto an SDS-PAGE gel, which showed a few crosslinked and correctly sized
particles, the best of which was found in fraction 2 (Figure 2.3.1). This crosslinked sample
was then applied to grids and stained with uranyl acetate resulting in seemingly well
behaved complexes. These complexes were roughly the same size, averaging 7 nm, well
within the expected size for a 400-600 kDa particle (400 kDa without Sm5, 600 kDa
saturated) (Figure 2.3.2). Given the few aggregates, apparent homogeny, and optimal stain
coverage and contrast, I collected two hundred images to begin classification.
Using 200 micrographs as a starting point, I selected >6000 to use for initial 2D
classification. I used RELION v1.3 as it was able to automatically reject some particles if
the micrographs were of poor quality. It is fast becoming the most used in electron
microscopy, and it has documentation and support enough for me to effectively use
it.(Scheres, 2016) I chose to have RELION preform reference free classification to ensure
no bias and let it assign the 4161 particles of high-quality into 100 classes. These classes
were then assessed by visual inspection, z score (a measure of how well the particles
aligned to the class), and number of particles per class, resulting in 40 favorable classes to
move forward (Figure 2.3.3). As a general rule, negative staining requires 20-50 particles
per class for acceptable sorting, and at least 16 classes in order to effectively capture
81

multiple orientations. Both of these criteria were met for the final product. The particles in
the high-quality classes are nearly all the same size and several of them appear to have the
same overall shape – both signs of homology. This suggests that most of the particles are
the same complex and they are sorted into too many classes. Apparent differences between
classes is likely due to a change in orientation (Figure 2.3.3). Negative stain greatly limits
the resolution of the particle, and all of this combined means the overall quality of the
particle and classification is high, but not perfect. The particles from these classes were
then classified a second time and sorted again into 100 classes to generate even higher
quality classes.(Elmlund et al., 2017; Milne et al., 2012; Scheres, 2016; Sjors H.W. Scheres
MRC Laboratory of Molecular Biology Francis Crick Avenue et al.) Using the same
selection criteria as before, the classes were pared down to 36 for 3D reconstruction and
represented 2318 particles.
Using the limited information provided by negative stain, I decided to generate a 3D model
of the particle. RELION outputs the 3D model as a volume, which I have presented here at
a level of 10 in Chimera, just before additional non-connected volumes appear (Figure
2.3.4).(Pettersen et al., 2004) It is interesting to note that there are some hollow spaces and
gaps between the structure, which might be an artifact of having different particles or might
also inform about a potential structure. The spread-out structure and difficulty in
classification of heterogeneity might be due to SMN being linked to one another through
the YG-Box with the amino terminus free to move about and dangle with Gemin2-Sm5
attached. Gemin2-Sm5 fits the best at the distal parts of this model. It seems unlikely there
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is room for four sets of MBPs and Gemin2-Sm5s. This apparent loss of density could be
accounted for through incomplete binding (either between Gemin2 to SMN or Sm5 to
Gemin2), flexibility in MBP, or other domains being averaged away. In a 4:4:4 complex
of SMN-Gemin2-Sm5 the mass would be 41% Sm5, 27% MBP, 20% Gemin2, and 12%
SMN, and as such two structures shown for MBP and SMNpeptide-Gemin2-Sm5 account
for nearly 90% of the volume, which should aid in assignment.(Quiocho et al., 1997; So et
al., 2016)
The structure of an SMN complex remains elusive, and while the EM structure for S. pombe
is promising it also is difficult to assess its accuracy. It is hard to say whether the model
might be slightly strained from the addition of MBP, which accounts for more than a
quarter of the total mass/volume. In its initial phases, this structure strongly supports the
idea that SMN is at its most basic unit a tetramer, which adopts an extended conformation.
There were no obvious Sm5 crescents seen in either the micrographs, classes, or model;
therefore, identifying their location is difficult. The location of Sm5, observed from the
classes as well as the 3D model, is more likely to be pointed outward from the central
complex pointing to an ease of access for both snRNA and SmB/D3 that is needed to
continue along the snRNP assembly pathway. This structure reaffirms S. pombe SMN as a
viable target and provides some hints about how the complex behaves. It will serve as a
good foundation for additional structural determination.

83

Figure 2.3.1 Crosslinked SMN-Gemin2-Sm5 complex for EM
Shown are the results of crosslinking SMN-Gemin2-Sm5 via GraFix technique using a
gradient of 10-30 w/v glucose and 0-0.1v/v glutaraldehyde, and ultracentrifugation, fractions
are shown from bottom to top 1-10. Fractions 1-5 show some crosslinked species with 1
being the heaviest and likely most crosslinked. To avoid aggregation fraction 2 was the one
used and applied to EM grids as it appeared to be approximately the correct size and as it
was not the bottom fraction should not have large aggregates. Visualized on 4-12% SDS
PAGE gel with MOPS intentionally overrun for more resolution of crosslinked species and
stained with comassie blue. Weight marker and input are shown before numbered lanes;
the input is at the actual concentration loaded onto the GraFix to show dilution effects with
uncrosslinked SMN and Gemin2 shown on the side. Sm5 components would have been
run off the gel and thus are not visible. Weight marker shown to the side with 25* showing
not the position of 25 but the bottom of the gel with the next band in the series, 25 kDa,
not on the gel.
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Figure 2.3.2 Sample micrograph of S. pombe SMN-Gemin2-Sm5 complex
A representative sample micrograph of negative stained (uranyl aceate), crosslinked S.
pombe SMN-Gemin2-Sm5 complex. Particles are of uniform size at 7 nm, have good
dispersion, and are what is expected for and ~600 kDa particle. A 10 nm scale bar shown
at the bottom. Image collected by Oris CCD camera with 50000 magnification on a Tecnai
TF20 operating at 200 kV.
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Figure 2.3.3 2D classification of S. pombe SMN-Gemin2-Sm5 complex
Top 40 2D classes of 4161 particles were boxed out of 148 micrographs, after disregarding
52 images because of severe astigmatism and too large of a focal distance. There are several
classes of particles that look nearly identical indicating acceptable levels of heterogeneity,
with some outliners representing either conformational or stoichiometric heterogeneity.
Image preprocessing and reference-free 2D classification were performed by using
relion1.3.
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Figure 2.3.4 3D model of S. pombe SMN-Gemin2-Sm5 complex
From second round 2D classification and selection to 36 classes an initial 3D model was
refined for S. pombe SMN-Gemin2-Sm5. This model in shown as a wire mesh with all six
faces of it shown with 90º rotations shown in respective directions. It is surprisingly flat
and long and has two areas of relatively little density between four lobes. For size
comparison and in an effort to visualize where the molecules might fit in, Gemin2 (red)
with Sm5 (yellow) with a small SMN fragment (blue) are shown from human crystal
structure 3S6N, and maltose binding protein (light blue) tag on SMN is shown from 4MBP.
Together these parts from known crystal structures represent 90% of the complex mass
with the remainder being the unknown parts of SMN.
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Assembly of snRNPs mediated by the S. pombe SMN complex
In vivo, the SMN complex is required for snRNP or Sm core assembly, but it is unclear
what components are sufficient for this function. Now that I was able to obtain all proteins
in the S. pombe SMN complex, Gemin2 and SMN, as well as all seven substrate Sm
proteins, the only remaining required component was the snRNA. I would need to generate
a model RNA to test both if SMN-Gemin2 influenced snRNP assembly and what effects
RNA would have on SMN-Gemin2 interactions and recycling. I chose to focus on the two
snRNAs most commonly used in snRNP assembly reactions, U1 and U4 snRNA.
All of the snRNAs in S. pombe contain the same structural features seen in more complex
organisms, importantly including the snRNP code (Sm site with 3’ stem loop), so these
results should translate well into more complex systems. Interestingly, in S. pombe, U1
snRNA features a perfect Sm site (AUUUUUG) while U4 snRNA deviates slightly
(AGUUUUG); this is opposite from what is seen in most other eukaryotes, including
human. From PCR products containing T7 RNA polymerase promotor and snRNA
sequences with and without Sm sites, I was able to generate large quantities of these
snRNAs. The lab has developed a high throughput and automated way of screening snRNP
assembly using biotinylated snRNAs and an Sm core specific antibody, Y12, which
recognized symmetrically dimethylated RGs on SmB, D1 and D3; however, I couldn’t use
this technique due to some differences in S. pombe Sm proteins and the lack of methylation
in E. coli expression.(Kaida et al., 2010; Wan et al., 2008) I instead chose to use a much
more traditional and simpler assay, an electrophoretic mobility shift assay (EMSA) which
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uses 32P 5’ radiolabeled snRNAs that will be retarded upon protein binding, which should
chiefly be Sm cores under 1 M urea conditions.(Guthrie and Patterson, 1988)
While I was unable to see any Sm core assembly on U1 snRNA despite its more canonical
Sm site, I was able to see a shift that with these high urea conditions could only be assembly
on U4 snRNA. The clear assembly of Sm cores on U4 snRNA is increased by the addition
of SMN and Gemin2, and was specific for the Sm site (Figure 2.4.1). SMN and Gemin2
specifically increased assembly most visibly with 0.2 molar ratio (20 nM) of Sm proteins
to 1 molar ratio (100 nM) of SMN-Gemin2, both of which far exceeded the levels of
snRNA despite the incomplete shift. Poor assembly for some U4 as well as for U1 could
be due to mis-folded snRNAs; although efforts were taken to refold immediately before
the reactions, it is likely that 120-140 nucleotides worth of RNAs can adopt different
confirmations in the absence of snRNP specific proteins or other chaperons.
While it might seem as though SMN-Gemin2 is a weak catalyst, it is likely that this is
entirely due to the low levels of Gemin2. In the reaction, the actual amount of Gemin2,
the true binder of the Sm proteins, is barely detectable due to low concentration, likely 10fold less than thought during snRNP assembly assays (Figure 2.4.2). The remaining
proteins are of very good purity and quality, with the exception of SmB which has some
truncations from full length. This is, to my knowledge, the first time appreciable amounts
of full-length SmB have been produced from E. coli, as all other reports use only the Sm
fold. The low catalytic activity could also be due in large part to the very low amounts of
protein being used, as the concentrations are near the Kd for both SMN-Gemin2 as well as
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Gemin2 Sm proteins.(Sarachan et al., 2012) Finally, the SMN-Gemin2 complex might
have evolved not so much as an enzyme for snRNP assembly, but as a check point molecule
to ensure assembly only on snRNA and not other uracil rich RNAs, stopping non-specific
RNAs at the cost of very quick Sm core formation.
This weak activity prompted me to look at what the snRNA was doing to complex
component interactions. The assembly assays showed no bands for SMN-Gemin2 binding
to snRNA. This is in direct contrast to human SMN’s non-specific RNA binding in exon
2, which does not have high conservation. I wanted to see if binding to snRNA affected
SMN-Gemin2-Sm protein interactions. Interestingly, the addition of snRNA decreases
association of Gemin2 and Sm5 from SMN (Figure 2.4.3). This effect was specific to
snRNA, as E. coli tRNA had no appreciable effect; furthermore, addition of all seven Sm
proteins completely dissociated Gemin2 from SMN (lane 12). It is important to note that
the addition of SmB/D3 to SMN-Gemin2-Sm5 has no effect on their associations without
snRNA (lane 6). With the addition of both SmB/D3 and snRNA to SMN-Gemin2-Sm5, a
mature snRNP core is formed. Consistent with EMSA data, this core is then released from
SMN-Gemin2, allowing for complex recycling and subsequent function in another round
of snRNP assembly, a key requirement for an enzyme.
The assembly of an Sm core from only SMN-Gemin2 and substrates is important not only
as the first direct demonstration of the sufficiency of SMN-Gemin2, but also of the ease in
which it is done. This activity requires no ATP or other chemical reagents, and no other
chaperones or proteins. While doubtlessly the Gemins that evolved in more complex
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organisms are important, here I have shown that Gemin2-SMN is the central core on which
snRNP assembly relies and conclude that Gemins3-8 and unrip serve in a regulatory and
auxiliary role. Further increase in efficiencies are likely achieved by some of these Gemins
as well as with the addition of the Tudor domain to SMN, which S. pombe lacks. The
cycling of SMN-Gemin2 off of mature snRNP cores is an important step in an enzymatic
cycle and should keep them from interfering with fully mature snRNPs. Taken together
with the requirement of Sm5 binding to Gemin2 to induce association with SMN, these
data fill in the largest blanks in the SMN complex’s role in the snRNP assembly pathway.
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Figure 2.4.1 Sm core assembly increased with S. pombe SMN-Gemin2
S. pombe SMN-Gemin2 is able to increase Sm core formation on a U4 snRNA through
specific attachment on the Sm site. Addition of Sm proteins F/E/G, D1/D2, and B/D3
(Sm7) to U4 snRNA, causes a shift consistent with Sm core formation. Some snRNP core
formation occurs in the absence of SMN-Gemin2 in agreement with literature results about
spontaneous formation and association (lanes 2-3).(Urlaub et al., 2001) SMN-Gemin2 is
effective in increasing snRNP formation resulting in more Sm core assembly than without
and can assembly them at lower concentrations (lanes 6-9). There are no strong bands or
association when the Sm site is removed (lanes 11-18). Under these conditions neither
SMN nor Gemin2 strongly associate with U4 snRNA. U4 snRNA and U4 ∆Sm snRNA
have some degradation seen below the main band, some of these products are still able to
assembly into snRNPs as seen in the tails of the Sm cores. The base amount of protein used
was 1 pmol (100 nM) for SMN with the corresponding ratios for Sm7 listed on the figure.
Results are visualized on an 5% PAGE, 1 M urea, Tris-Glycine gel by 32P labeling on U4
snRNA and U4 DSm snRNA detected by film exposure.
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Figure 2.4.2 SMN-Gemin2 and Sm7 proteins used in Sm core assembly
Proteins used for S. pombe SMN-Gemin2 assembly assays are of high-quality and purity
for SmF/E/G (lane 3) and SmD1/D2 (lane 4) as well as SMN (lane 1), SmD3 of SmB/D3
is high-quality with SmB showing several species of truncation although all likely include
the Sm fold and are only degraded at the RG rich CTD (lane 5). Gemin2 is considerably
lower in concentration than SMN and the other proteins although present (lane 1). The low
levels of Gemin2 are likely due to the co-purification of SMN-Gemin2 through specific
tags on each protein. Inputs used at 5 pmol (5-50x concentration used) and lanes 1 and 2
show the reagents added to each assembly reaction according to their amount. Visualized
by silver staining of 12% SDS-PAGE gel.
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Figure 2.4.3 Assembled snRNP core releases Gemin2 from SMN
Gemin2 shows a weak affinity for SMN without SmD1/D2 and SmF/E/G (Sm5) (lane 1)
then becomes a tight binder in their presence (lanes 5-6). Binding of Gemin2 to SMN and
perhaps Sm proteins to Gemin2 is reduced with U4 snRNA (lanes 11-12). Full product
release appears to occur when SmB/D3 are present and snRNP core can be made (lane 12).
Non-specific RNA, E. coli tRNA, appears to have no effect on SMN-Gemin2-Sm
interactions (lanes1-6). Interactions are demonstrated by using MBP-SMN from on
amylose beads. The total lanes show 10% of the recombinant proteins for the binding and
the gels are visualized by silver staining of a 10% SDS-PAGE gel.
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Gemin2 ortholog Brr1 contains SMN-like functions
One of the simplest eukaryotic organisms is the brewer’s yeast S. cerevisiae. Fittingly, they
also utilize the simplest SMN-like complex. Multiple sequence alignments do not indicate
SMN’s presence in S. cerevisiae, but do show a likely Gemin2 ortholog, Brr1, which
contains additional regions compared to Gemin2 found in species with SMN (See Figures
1.2.4 and 2.1.5 presented earlier). Brr1 was first identified by the Guthrie group; they found
deletion of this gene caused a cold sensitive toxicity. These Brr1 knockout yeast failed to
grow at room temperature, but otherwise grew normally at their optimal temperature (30
˚C). Further probing by the Guthrie group found Brr1 knockouts contained fewer
spliceosomal snRNAs while other small RNAs remained unchanged. Furthermore, the
toxicity from this mutation was partially suppressed by additional expression of Sm
proteins.(Noble and Guthrie, 1996; Noble and Guthrie, 1996) Work concurrent with that
presented here also highlights important relationships between Brr1 and Sm proteins
through site directed mutagenesis genetic studies in yeast.(Schwer et al., 2017) Here, I will
show for the first time direct, biochemical, in vitro evidence for Brr1 association with Sm
proteins including SmB/D3 which no other Gemin2 binds, and that Brr1 acts as a catalyst
for Sm core assembly.
I cloned and expressed Brr1, and all seven of the Sm proteins from S. cerevisiae. Both
SmD1 and SmB required being truncated to the Sm core and SmD2 needed an MBP tag
for solubility, but all others were well behaved as full-length constructs. Having produced
these reagents, I sought to test their biochemical usefulness. Using Brr1 fused with a
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glutathione S-transferase (GST) tag as bait, I probed for Sm protein interaction.
Surprisingly, Brr1 bound to each hetero-unit of Sm proteins (SmB/D3, SmD1/D2, and
SmF/E/G) individually and in combination, indicating unique or potentially independent
binding surface for each of them (Figure 2.5.1). In an attempt to further delineate binding
capacity, I made fragments of Brr1 NTD (a.a. 1-64) and CTD (a.a. 81-341). The design of
the NTD was based on the high degree of conservation for the SmF/E/G binding helix, and
terminated just prior to an unstructured, non-conserved region between amino acids 64 and
81. The CTD started at amino acid 81, just before several predicted helices, which likely
form the four helical bundle core seen in Gemin2 crystal structures. These domains showed
the same SmF/E/G and SmD1/D2 binding pattern as human and S. pombe, with NTD
binding to SmF/E/G and CTD to SmD1/D2 independently. SmB/D3 showed little to no
affinity for either domain of Brr1, suggesting either that it requires the missing amino acids
65-80 or that it has extended, albeit weak, contacts with both domains. Interestingly, upon
addition of all 7 Sm proteins, SmB/D3 as well as SmF/E/G bound to the CTD. These results
indicate that the CTD likely has strong contacts with a snRNP core. With all seven Sm
proteins present, SmD1/D2 also had increased CTD affinity, hinting that it recruits
SmB/D3 which only has a small binding surface for the CTD. Thus, B/D3 creates a new,
much larger and stronger binding surface through SmD1/D2 interactions. Fascinated that
Brr1 binds all of the substrate proteins, I next wanted to see if Brr1 could bind a substrate
RNA, something Gemin2 does not do and another potential source of increased function.
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In order to assess if Brr1 would bind to RNA and make an Sm core, I first had to make a
model RNA. Given the large size of U1 and U2 snRNA, and the importance of Sm core
formation on the RNA of telomerase in S. cerevisiae, I decided to test assembly on a model
yeast telomerase RNA. I made an Sm site containing minimal version of TLC1 RNA, that
I termed µTLC1, consisting of just the defined Sm protein binding portion of the Cech
lab’s mini-TLC1 (Figure 1.5.2).(Cech et al., 2005) It is worth noting that, unlike most
other eukaryote’s snRNA, there is no 3’ stem-loop of the Sm site in S. cerevisiae TLC1. In
fact, the downstream sequence, although not conserved, does have a length of 6-10 nt found
in U1, U4, U5, and TLC1, and this may function as a way to increase spontaneous or Brr1
mediated assembly, and may provide more insights into how S. cerevisiae assembles
snRNPs different, and its ability to survive Brr1 knockout under permissive conditions.
Sm proteins have long been known to assemble spontaneously on Sm sites. Accordingly,
when I add all seven Sm proteins SmB/D3, SmD1/D2, and SmF/E/G to µTLC1 at various
concentrations I see some amount of Sm core or snRNP assembly (Figure 2.5.3).(Guthrie
and Patterson, 1988) Importantly, addition of substoichiometric levels of Brr1 greatly
increase the amount Sm core formation, with likely the maximum achievable seen in lane
8. Thus, Brr1 is robustly proven to enzymatically facilitate snRNP assembly.
Unexpectedly, Brr1 at equimolar or greater ratios inhibits snRNP assembly (Figure 2.5.4).
Brr1 also appears to lack, or at least have very weak binding to Sm site containing RNAs,
and this is disrupted by the 1 M urea in these gels (Figure 2.5.3 lanes 2-3 and Figure 2.5.4
lanes 2-3 & 11-12). Interestingly, addition of Brr1 to µTLC1, independent of Sm site,
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causes a smeared shift and suggests that there might be some specificity or binding to a site
outside of the Sm site with the addition of Sm proteins. This could be either caused by a
newly formed and shared surface between Brr1-Sm5, or prompted by an allosteric change
in Brr1, whereby an RNA binding surface becomes active (Figure 2.2.4 lanes 7-9 & 1415). The disparity between Figures 2.2.3 and 2.2.4 where addition of Brr1 causes a shift in
free probe could be due to differences in RNA concentration, gel consistence or
temperature, mixing, or other experimental variations. All of these factors were controlled
for as best as possible, including using RNA within two weeks or one 32P half-life of each
other and ensuring minimal changes in concentration. Alternatively, and most likely, the
degree of Sm core assembly and shift of Brr1-Sm5/7 species in the gel is due to an increase
in the base of amount of protein loaded, from 100nM to 250nM.
These results substantiate Brr1 as a true Gemin2 ortholog and a SMN-Gemin2 paralog.
Showing that Brr1 can uniquely bind all protein substrates: SmB/D3 like SMN and
SmD1/D2 and SmF/E/G like Gemin2 is important for assessing what is required of snRNP
assembly factors in divergent organisms. This remarkable protein also seems to have some
affinity for RNA, similar to SMN’s non-specific RNA binding in exon 2, which might
serve to orient or allow the sliding of substrate RNAs. Brr1 is also directly capable of
catalyzing Sm core formation, supported by lower levels of snRNA/snRNPs in Brr1
deficiency as well as Sm core formation being dependent on both concentration and
temperature. As the first direct and entirely recombinant demonstration of Sm core
catalysis, these results are significant. While catalytic activity has been demonstrated for
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human SMN through depletion and rescue experiments from cell extracts, this is the first
Sm core catalysis demonstrated using only recombinant proteins. The cold sensitivity,
complementation of Brr1 with Sm proteins, and lack of ATP requirement tell us that, in
this very simple SMN system, Brr1 first evolved to push forward a natural process and
accelerate snRNP core formation. Thus, the Gemin2 ortholog Brr1 serves as the basic unit
of the SMN complex, and functions to mediate snRNP assembly.
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Figure 2.5.1 Brr1 interacts independently with each subunit of the Sm core
Full-length Brr1 shows affinity for each of set of Sm proteins (SmB/D3, D1/D2, and F/E/G)
in lanes 5-9. The NTD (1-64) of Brr1 shows F/E/G affinity (lanes 11 & 12) and the CTD
(80-341) shows affinity for Sm B/D3 and D1/D2 (lanes 13-16). The NTD and CTD
interactions with SmF/E/G and D1/D2, are identical other Gemin2s. There is a novel
interaction of SmB/D3 on the CTD, which is weaker alone (lane 20), but may be aided by
Sm-Sm interactions (lane 16). This is nonetheless a demonstration of Brr1’s ability to bind
all the protein substrates of the Sm core. Interactions are demonstrated by using GST-Brr1
pull-down from on glutatione beads. The total lanes show 10% of the recombinant proteins
for the binding and the gels are visualized by silver staining.
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Figure 2.5.2 Architecture of µTLC1 RNA
RNA for Sm core assembly chosen as a much smaller version of miniTLC1 termed µTLC1.
This RNA contains the Sm site (highlighted in yellow) found in TLC1 as well as elements
of a long stem with connects the Sm site to the rest of TLC1/miniTLC1 at nt 34, which was
shortened for simplify. Architecture generated via m-fold, Sm core assembly is predicted
to destabilized final stem loop at 53-60.
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Figure 2.5.3 Brr1 catalyzes Sm core formation
Brr1 is able to catalyze Sm core formation on a model RNA through specific attachment
on the Sm site. Addition of Sm proteins F/E/G and D1/D2 (Sm5) and SmB/D3 (100 nM)
to model RNA, µTLC1, causes a shift consistent with Sm core formation. A small amount
of the Sm5 and snRNP core bands can be seen even without Brr1 in agreement with
literature results about spontaneous formation and association (lanes 4-6). Brr1 is effective
in catalyzing snRNP formation resulting in nearly complete Sm core assembly at a 1:10
ratio Brr1:Sm7 (lane 8). Interestingly equimolar ratios of Brr1:Sm5/7 (lanes 6 & 7) appear
no different than without Brr1 showing a stalled progression. This halt is most likely due
to the requirement that reagents displace product on Brr1. Brr1 serving to hold the reaction
in a state that easily goes both forward and backward. There are no strong bands or
association when the Sm site is removed (lanes 10-14), nor does Brr1 strongly associate
with the RNA (lanes 2& 3). Results are visualized on an 5% PAGE, 1 M urea, Tris-Glycine
gel by 32P labeling on µTLC1 and µTLC1 DSm detected on film.
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Figure 2.5.4 Excess Brr1 limits Sm core formation
At stoichiometric or super-stoichiometric levels Brr1 is able to stop formation of Sm cores
on model RNA. Addition of Sm proteins F/E/G and D1/D2 and SmB/D3 (together Sm7,
250 nM) to model RNA, µTLC1, causes a shift consistent with Sm core formation. At these
levels of Sm proteins spontaneous formation of Sm core is nearly complete (lanes 4-6).
Equimolar or super-stoichiometric ratios of Brr1:Sm7 (lanes 7-9) stall or have incomplete
snRNP assembly. Removal of the Sm site (lanes 10-15) does not show specific snRNP core
formation; however, in the presence of Brr1 there appears to be minimal binding to RNA
enhanced by Sm7 that is non-Sm core. Results are visualized on an 5% PAGE, 1 M urea,
Tris-Glycine gel by 32P labeling on µTLC1 and µTLC1 DSm detected on film.
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Biological Significance Behind the Expression of SMN Complex
Components
Modification of SMN and Gemin2 levels in Schizosaccharomyces pombe
Given the newly discovered and regulated interaction between SMN and Gemin2 whereby
they are not required to be in a 1:1 complex, as well as the significance SMN amount in
SMA, I decided to modulate both SMN and Gemin2 levels in S. pombe, to see if there were
any effects of pushing SMN-Gemin2 ratios away from 1:1. Interestingly, similar to most
other eukaryotes there is only one copy of SMN in S. pombe (Yab8); however, there are
two copies of Gemin2, Yip11 and Yip12 (Yab8 interacting protein 1[1 or 2]) which have
identical pre-mRNA sequences. The two copies of Gemin2, hereafter Gemin2-1 and
Gemin2-2, will allow us to easily lower Gemin2 levels by knocking out a single copy;
further modulation could be achieved by incorporating the nmt81 promoter upstream of the
remaining copy, Gemin2-2. This promotor will reduce expression in the presence of
thiamine (thia) and has the lowest baseline expression for the nmt family of promotors. As
SMN is essential in S. pombe, I chose to knock-in a modulatable promoter, Tet-off, which
reduces expression in the presence of tetracycline or doxycycline (dox). With the help of
an experienced yeast geneticist and labmate, Chie Arai, we created four strains for further
experiments, wildtype [wt], Tet-off SMN [SG1], Tet-off SMN + Gemin2-1 knockout
[SG2], and Tet-off SMN + Gemin2-1 knockout + nmt81-Gemin2-2 [SG3]. All strains with
Tet-off SMN had the interesting effect of growing better than wild-type, which we
explained by the increase in SMN levels. Due to the low levels of endogenous SMN and
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Gemin2, western blots failed to detect levels of SMN in wild type cells, although it could
be seen in some conditions for Tet-off SMN; Gemin2 had similar detection
problems.(Marguerat et al., 2012)
Using these four strains, we were able to test viability of S. pombe as a proxy for toxicity
of Gemin2 under four conditions: Edinburgh minimal media (EMM), EMM + 7.0 µg / mL
dox, EMM + 6.5 µg / mL thia, and EMM + 7.0 µg / mL dox + 6.5 µg / mL thia. These
results are visualized in Figure 3.1.1 and summarized here. SMN levels would be lowered
drastically with dox treatment, which caused toxicity in all sensitive strains (SG1-3), but
had reduced relative toxicity when Gemin2-1 was knocked out (SG2). Likely due to an
increase in expression under nmt81 promotor, there was no noticeable change in growth of
this strain (SG3) despite Gemin2-1 knock out. These results are consistent with both SMA
pathology and SMN’s necessity in S. pombe. Attempting to modulate Gemin2 levels
through thia addition had the interesting effect of increasing cell growth for all cells. This
growth increase also affected wild type, and thus was likely due to the advantage this
nutrient provided on the required minimal media; therefore, thia containing plates can only
be looked at in terms of relative growth on the same plate. Lowering Gemin2 with this
method did not affect growth, even in SG3, with high levels of SMN. Combining both the
dox and thia additions reduced growth similar to dox only for SG1 and SG2, however, SG3
had better growth. These results show that Gemin2 levels exceeding SMN capacity are a
source of toxicity, while simply lowering SMN levels is not as deleterious if Gemin2 levels
are managed.
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With the novel finding that high levels of Gemin2 in the absence of SMN are toxic, it is
critical to determine the mechanism of this toxicity. It is likely that the exposed
hydrophobic areas in Gemin2’s SMN binding pocket are what induce toxicity, as this is
where SMN would bind in the presence of Sm proteins and where the NTD would bind
without them. Thus, mapping which fragments of Gemin2 are toxic and which of SMN
rescue is an important first step. Interestingly, it has already been shown that both the
Gemin2 binding domain and the YG-Box in SMN are required for S. pombe viability.
Some work has been reported on characterizing SMN’s domains in S. pombe, and their
functions in cells with very low levels of SMN and unmodulated Gemin2. In these cells
overexpression of full length SMN (greatly above normal levels) and to a greater extent
SMN lacking Gemin2 BD were toxic. Interestingly overexpression of the portion SMN
containing Gemin2 BD was not toxic, and thus this fragment alone could be useful to
combat Gemin2 overabundance with minimal risk.(Paushkin et al., 2000) These results
are important to replicate in other types cells and species, as only Gemin2 overexpression
as being toxic in S. pombe has been reported by another group concurrent to data presented
here.(Borg et al., 2015) The next step was to look and see if a Gemin2:SMN imbalance
was present in SMA patients, if the imbalance was present it would indicated Gemin2 as
potential therapy target.
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Figure 3.1.1 Growth of S. pombe with perturbations in SMN and Gemin2 expression
Four strains of S. pombe, wildtype and SG1-3, were plated in a fivefold dilution series on
EMM plates with: nothing extra, 7.0 µg/mL doxycycline (dox), 6.5 µg/mL thiamine (thia),
or both dox and thia. The strains SG1-3 contained modification to SMN’s (Yab8) promotor
to Tet-off (SG1-3), ∆Gemin2-1(Yip1, SG2-3), and modification of Gemin2-2’s (Yip12)
promotor to nmt81 a Thia-off (SG3) as indicated in the chart; with “-” indicating no change.
SMN levels were reduced by addition dox and similarly, Gemin2-2 levels were reduced
with thia. SMN reduction showed decreased growth, reduction of both SMN and Gemin2
partially restored growth to wild-type levels. Plates were incubated for 48 hr at 30°C,
shown after imaging by scanning and level adjustment for contrast.
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SMN complex component levels in SMA patient derived cells
Having found that reducing Gemin2 levels aided growth in S. pombe cells with low SMN,
I wanted to see if this Gemin2:SMN imbalance occurred elsewhere. Immediately apparent
was that many SMN knockdowns, specifically through RNAi and shRNA, seemed to affect
both SMN and Gemin2 levels. Although unreported, this co-reduction was not seen in
mouse SMA models, and thus I wanted to look at SMN and Gemin2 levels in SMA using
the four SMA lymphoblast fusions available from the Corriel Institute (three type I and one
type III). Gemin2 is the only component of the SMN complex so far to have different levels
of expression dependent on technique with which SMN is reduced. One of these cell lines
(GM23686) had accompanying cells from both parents, but there were no age or gender
comparable cells from other individuals. In order to find appropriate controls, I chose not
to use previously studied pairs as they came from patients who suffered from other
diseases. Instead, I aimed to use some of the very few lines with matching age and gender
that had displayed no clinical phenotype, although all of them were related to disease
suffering patients and may have carried recessive or sub toxic alleles for various diseases.
It is important to ensure that cells are age match as evidence for variable expression of
SMN in SMA modes has been shown.(Zhang et al., 2008; Zhang et al., 2013) The cell
types used and patient information is summarized in Table 3.2.1.
As expected in SMA patient cells, there is a dramatically lower level of SMN. Interestingly,
and previously reported, Gemin8 levels are also reduced and so shows some of the Gemins
are co-regulation with the SMN. Unlike when SMN is knocked down in HeLa or other
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cells through RNAi, Gemin2 levels do not appear to have decreased significantly. Gemin5
levels remain constant in both SMA and control as expected. Levels of one substrate
protein, SmD3, also did not change between SMA and controls. All of this is summarized
in Figure 3.2.1. When comparing levels of SMN complex components to SMN itself, it is
clear that there is a 2-4-fold increase in both Gemin5 and, importantly, Gemin2 in SMA
patients compared to their controls. This change is not observed for Gemin8 however,
which shows less than a 1.5-fold increase at most (Figure 3.2.2). In comparison to Gemin8's
tighter association with SMN levels, Gemin2's regulation and protein level fluctuations
further suggest that it indeed can and does act as a free agent, at times not bound to SMN.
The important changes in the SMN:Gemin2 ratio in vivo and how SMN and Gemin2
interact as shown in vitro strongly suggest that a disruption to Gemin2’s function in
signaling the presence of Sm5 to SMN is vital to cell. This new-found regulation when
aberrant is a potential additional source of toxicity in SMA, and modulating this is worth
perusing as a mitigating treatment. It is especially interesting that this effect is seen to be
stronger in SMA type I rather than type III; however, given the very limited sample
numbers, this trend is merely suggestive and cannot be definitively proved. The trend of
increased Gemin2:SMN ratio in SMA cells are also only shown in one type of
immortalized cell line. More work needs to be done to see if this is true in primary cells
and those cells most affected by SMA, namely motor neurons and associated cells. One
suggestion that this may be a more general phenomenon is that western blots from SMA
model mice appear to show the same pattern in specific tissues.(Zhang et al., 2008) While
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the authors do not specifically comment on this their blots nonetheless show the same
pattern. Targeting Sm5 primed Gemin2 in SMA patients might have the effect of creating
more mild symptoms. It may prove easier to lower protein levels or block toxic surfaces
than to increase protein amounts with traditional small molecule drugs. These lead to the
interesting possibility that a paradigm shift such as this could soon lead to an easy therapy
for SMA.
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Figure 3.2.1 Western Blot of SMN Complex components in SMA derived cells
Patient derived lymphoblasts from SMA patients as well as age and gender matched
controls, show a decrease in SMN and Gemin8 protein levels. SMA does not appear to
affect Gemin2, Gemin5 and SmD3 levels. Also shown are tubulin loading and
normalization controls for the two respective blots. Blots were run from ~10 000 cells lysed
in SDS-PAGE buffer and loaded onto 2-12% SDS-PAGE in MES buffer, blotted for
identified target protein using Licor system.
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Figure 3.2.2 Levels of SMN complex components normalized to SMN levels
Graph showing amount of Gemin2 (red), Gemin5 (yellow), Gemin8 (green) and SmD3
(blue) compared to SMN levels normalized to controls (GM06142, GM06143, GM12497,
and GM09457 respectively) for SMA type I (GM23686, GM23688, and GM10684) and
type III (GM23255) of Coriell Institute lymphoblasts. Gemin2, Gemin5 and SmB3 ratios
dramatically increase in SMA type I and less so in type III whereas Gemin8 ratios are
nearly the same.
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GM10684

GM23255

SMA III

Table 3.2.1 SMA patient derived cells information
This table summarizes cell lines used and contains potentially relevant information. Listed
by Coriell ID number characteristics include: disease suffered or disease related to (SMA
and type, Adenosine Deaminase Deficiency [ADA], Cockayne Syndrome type A [CS-A],
and Usher Syndrome type 1C[USH-C1]), whether or not patients are affected by the related
disease, any mutational information, gender and age as well as relationship to SMA
affected cells. Controls were age and gender matched as best as possible from Coriell
catalogue as long as they were unaffected by any known disease. Cells are listed by order
on Western Blot with controls following the SMA cell they were used for and related
groups blocked together.
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SMA Patient Lymphoblast Information
ID

Disease

Affected

GM23688

SMA I

GM23687

Gender

Age

No

Male

-

SMA I

No

Female

-

GM23686
GM06142
GM23689

SMA I
ADA
SMA I

Yes
No
Yes

Female
Male
Male

7 Mo
1 Yr

Control

GM06143

ADA

No

Male

9 Mo

Control

GM10684
GM12497
GM23255
GM09457

SMA I
CS-A
SMA III
USH-1C

Yes
No
Yes
No

Female
Female
Male
Male

6 Mo
7 Mo
16 Yr
18 Yr
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Mutation

P297Q
R149Q;
P297Q
Δ Ex7-8

Relation
Father
23686
Mother
23686

Control
Control

Conclusions
Impact on the RNP and SMA/SMN field
The SMA field has long been focused on SMN, but with the recently discovered
importance of Gemin2 in our lab and through the work I presented here, the focus should
shift to Gemin2 or Gemin2-SMN complex. Gemin2 can cause toxicity in SMA like
conditions, potentially explaining SMA as a disease caused by both an SMN deficiency
and a Gemin2 toxic gain of function. The long-held belief that SMN and Gemin2 formed
and unbreakable bond will begin to reduce.(Sarachan et al., 2012) In its wake, a more
defined and clear RNP assembly pathway is utilized. This pathway features clearly defined
steps in arranging seven Sm proteins specifically on an snRNA, and has several places for
additional regulation. Assembly of an snRNP core from recombinant proteins, shown in
two model systems, solidifies that the SMN complex components SMN and Gemin2 are
necessary and sufficient for their assembly, and enables detailed mutagenesis and
mechanistic studies to be performed.
Only recently with the new more central role of Gemin2 has the field begun to look at its
associated biology. During the course of this work, Ruben Cauchi’s laboratory concluded
that over-expression of Gemin2 can be detrimental in S. pombe.(Borg et al., 2015) Here, I
show that it is not excess Gemin2 per se, but rather an excess relative to SMN that is
deleterious. Gemin2’s contributions to snRNP assembly and its potential to attenuate SMA
disease manifestations challenged our previous understanding of the SMN complex and its
role in snRNP assembly and disease. While demonstration of Gemin2 toxic gain of
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function is new to the field, the imbalance between SMN:Gemin2 ratios is new only in the
attention it has received. Published work by others contain results showing an excess of
Gemin2 to SMN in various SMA disease models, but they did not further discuss the
implications of this imbalance.(Gabanella et al., 2007; Jablonka et al., 2002; Zhang et al.,
2008; Zhang et al., 2013) Further interest might also come from why some methods of
SMN knockdown decrease Gemin2 proportionally while others do not, potentially leading
to useful mechanisms by which SMN complex components are regulated and thus open up
new therapeutic avenues. These results should encourage exploration of the Gemin2:SMN
imbalance toxicity in a host of systems and cells, particularly to see if they contribute to
differential outcomes of patients with the same type of SMA. The determination of what
causes the toxicity also need further exploration, be it the characteristics of Gemin2 itself
or the proteins it interacts with. Despite this uncertainty, these results strongly suggest that
Sm5-bound Gemin2 is poised for snRNP assembly and has a large, exposed hydrophobic
patch. This is a feature associated with the pathology of many other diseases, and is mostly
the prime contributor towards toxicity in this case as well.
The paradigm of SMN and Gemin2 being independent of one another is an exciting new
place for SMN complex research. While here I address some of what Gemin2 is doing
without SMN, folding in on itself and waiting for Sm5 to come along to kick out the NTD
so Gemin2 can open up and bind to SMN, more can still be learned. Furthermore, what
SMN is doing without Gemin2 remains nearly completely unexplored. With this new
realization, it is likely that the field will be far more comfortable going back to data that
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was unexplainable at the time, such as some proteins associating with SMN’s Gemin2 BD
or the independent association of other proteins with Gemin2, and drawing new
conclusions.(Gertz et al., 2012; Wilfried Rossoll et al., 2003)
The binding of Sm5 to Gemin2, and subsequently to SMN, causes a cascade that drives the
SMN complex forward in snRNP core assembly. These results especially clarify important
steps early in snRNP biogenesis, such as the architecture and organization of Sm proteins
before the potential introduction of snRNA. In S. pombe it is clear that binding to snRNA
changes how Gemin2 interacts with SMN, likely through weakening Gemin2-Sm5
interactions when it is bound in the Sm5 crescent, adding yet another point of regulation
and communication to SMN complex mediated snRNP assembly. These results expand the
old, nondescript “Sm proteins are recruited to the SMN complex and with snRNA delivered
by Gemin5 then an Sm core is assembled” explanation out into several new steps. First,
Gemin2 alone in the cytoplasm has its NTD tucked into its SMN BD where it breathes
open for a moment to grab Sm5 from the methylosome. Exposed, the hydrophobic surface
of Gemin2’s SMN BD quickly searches for a new partner, which it finds with SMN. The
binding of Gemin2-Sm5 to SMN likely changes the structure of the SMN complex,
potentially setting off a cascade felt by the other Gemins. After several other likely
rearmaments, snRNA, potentially freed from Gemin5, enters Sm5 on Gemin2 and weakens
Gemin2-SMN interactions. This presents an opportunity either for other Gemins to replace
Gemin2 on Sm5 or for SmB/D3 to be deposited on SMN-Gemin2-Sm5. Upon the addition
of SmB/D3, Gemin2 loses most of its affinity for SMN, and likely the Sm core as well.
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With the release of Gemin2 and snRNP core form the SMN complex, both the SMN
complex and Gemin2 are ready to be recycled into another round of snRNP assembly. This
pathway is highlighted specifically for S. pombe, but is almost certainly occurring in higher
organisms with more steps involving other Gemins is shown in Figure 4.1.1.
Many of these results and the elaborated snRNP assembly pathway are possible only
because of an entirely recombinant protein system. This is, to my knowledge, the first
demonstration of the assembly of Sm cores from recombinant proteins. The use of such a
system and proteins should give the field a new and much more powerful tool to further
dissect the snRNP assembly pathway and mutations in complex components. Since these
experiments were conducted in S. pombe, we now know, at the very least, that SMN and
Gemin2 are sufficient for snRNP assembly in S. pombe. This will also help to direct the
field to focus on these two core components, partially bypassing the need for other Gemins,
several of which have yet to be produced in full-length from any system. Using this system,
and incorporating SMA causing mutations, should help further understanding of
deficiencies in snRNP assembly in SMA and separate it from other distinct mechanisms of
the disease.
These results will have the effect of making work on SMA and the SMN complex focus
on Gemin2, not as a nondescript SMN interacting protein, but instead as the center of
snRNP assembly. The ordered process of snRNP assembly has functioned in very primitive
eukaryotes through sequential addition of Sm5, Gemin2, SMN, snRNA, and SmB/D3 for
eons. Through these data and the work of others, nature’s secrets behind snRNP assembly
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are now becoming clear to us. Using a relay of allosteric changes, Gemin2 interactions
with SMN’s potential to act as sensors shows the detail of a finely tuned machine made for
RNP assembly in the SMN complex. These insights could shed light on many other RNAprotein particles; their interactions, production, and regulation. Excess Gemin2 compared
to SMN is toxic and, perhaps more importantly, this perturbation is seen in SMA, giving
us the first new target for the disease since the discovery of SMN itself. All of these create
exciting new directions in RNP assembly and translation of basic science into therapeutics,
and should shape a large segment of the field to come.
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Figure 4.1.1 Detailed snRNP assembly scheme for SMN-Gemin2
A scheme for snRNP assembly in S. pombe and showing new intermediates also present in
human. The pathway being with Gemin2 (red) auto inhibited with NTD and CTD
connecting (Step I). SmF/E/G (light orange) and SmD1/D2 (orange) bind to Gemin2
releasing Gemin2’s NTD from the CTD (Step II), this allows Gemin2 CTD to bind to SMN
(purple) through SMN’s Ge2BD (Step III). Next snRNA enters the cleft on the Sm
pentamer (Step IV). Finally, SmB/D3 (yellow) close on snRNA bound to the Sm pentamer
forming a snRNP core (Step V), SMN, Gemin2 and snRNP core are now released from
one another where they can go on to function in another assembly round and splicing (Step
VI). In S. pombe SMN is a tetramer and in other ekaryotes it is often more than a tetramer,
for most steps SMN is shown only as a single protomer for simplicity. Proteins are drawn
as cartoons roughly to scale with one another, RNA shows only the snRNP code and some
surrounding sequence rather than the entire snRNA and is not to scale. In the case of S.
pombe there are no known interactions between SmB/D3 and SMN nor SmD1; however,
in other eukaryotes that is not the case and SmB/D3 and snRNA are likely positioned on
SMN or other Gemins during the cycle, but still add to the snRNP core similarly.
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Future Directions
Much of the work presented here shows the clear importance of Gemin2, both in snRNP
assembly and disease; however, there are several more avenues to explore and important
ideas to build off of. Key to understanding SMA fully is the realization of a high-resolution
structure of the SMN complex in several states. In particular, more information about what
free Gemin2 looks like is important. Equally important, if not more so, is to establish a
mechanism by which Gemin2 excess confers toxicity. Finally, the toxicity of excess
Gemin2 in SMA patients and additional model systems needs to be directly confirmed.
These provide very broad and important directions that should be followed to build upon
to enhance this body of work, as well as drive the field forward.
A high-resolution structure of SMN has often been thought of as a holy grail for the field.
Given the information already presented here, using S. pombe SMN-Gemin2-Sm5 as a tool
to build on, a high-resolution structure is likely not far off. Further work needs to be done
to optimize the amounts of each peptide added, and establish reliable crosslinking and
purification techniques to ensure native levels of saturation for each of the complex
components. To address these concerns, it may be worthwhile to generate Sm-Sm fusions
and perhaps fusions SMN or Gemin2 to reduce stoichiometric heterogeneity, or to try and
extract and directly image native S. pombe complexes. These complexes should certainly
yield more structural information through the use of cryo-EM, and may present a complex
stable enough to crystallize. Additionally, SMN either alone or with Gemin2 CTD might
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tell us what SMN is doing without Gemin2 primed Sm5, and would represent a significant
and obtainable advancement.
Structural information about Gemin2 in an auto-inhibited state is also important for further
understanding of this model. The gold standard for this is, as stated previously, X-ray
crystallography, and again S. pombe Gemin2 may prove key with its stabilizing mutations
such as S118D with a more truncated NTD. These results also suggest that difficulties seen
by many researchers trying to get Gemin2’s structure might be aided by using CTD with a
small free peptide composed of the minimal sequence in Gemin2’s NTD to which it binds.
Such structures would likely require additional mutagenesis and truncation for accurate
mapping, which themselves would prove useful. Mapping of the binding site could also be
accomplished through differential labeling of residues with hydrogen and deuterium in
several different conditions: Gemin2 FL, Gemin2 CTD, FL + Sm5, CTD + Sm5, FL +
SMN pep, CTD + SMN pep, among the most promising. This labeling could be visualized
through NMR, but most easily through mass spectrometry. Comparison of labeling
between conditions will show both where and how long/strong the CTD-NTD binding is.
It will also provide good references for the several proposed states that Gemin2 finds itself
in with different binding partners. Although single amino acid resolution is obtainable
through mass spectrometry, the easier and nearly as useful resolution of 2-5 residues will
still show definitive binding.
These data suggest the likelihood of an SMN complex that does not always contain
Gemin2. Due in no small part to this, many questions about such a complex should be
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asked, such as: What is SMN’s structural arrangement, specifically is its Ge2BD buried?
Does SMN use its now freed Ge2BD to bind other proteins? How many Gemin2s are there
per SMN, and does Sm core assembly require a specific number? How does the presence
or absence of Gemin2 affect other Gemins binding? Are there different SMN complexes
with different functions? What is nuclear Gemin2 doing if snRNPs are not normally
assembled there, does it participate in some sort of recycling of mature snRNPs or make
other RNPs? Answering these broad questions is of fundamental importance and will
require significant resources. Many of these questions have existed in the field for some
time, but the data presented here give them new gravity and the results will be seen in a
new light.
From the data presented here, it is clear that excess Gemin2 relative to SMN is toxic;
however, even the beginnings of a mechanisms remain to be explored. There are several
possible mechanisms ranging from aggregation to aberrant interactions. The possibility for
Gemin2 aggregation or sequestration to a particular part of the cell is attractive given the
exposed hydrophobicity we propose, and needs to be looked at through microscopy.
Finding new interactions in the toxic state through IP-MS on SMA and control cells lines
is a straightforward experiment. New interactions will likely include other macromolecules
such as chaperones and perhaps other RNPs, or perhaps interactions will occur with other
proteins prominent in different pathologies. Understanding these modes of toxicity will
undoubtedly aid in the development of a plan to combat them and lead to more experiments,
including confirming modulating genes.
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Establishing Gemin2 excess relative to SMN in SMA needed careful exploration, mainly
through further confirmation. The change in levels for both proteins must be confirmed in
a broader group of patients, in different cell and tissue types, and from primary rather than
immortalized cells. After confirmation, the difficult task of developing a mammalian model
system can begin. A direct test of toxicity on the SMA cells used here should be performed
by reducing Gemin2 and assessing the fitness of these cells compared to control. Ideally, a
model human cell line where both Gemin2 and SMN levels can be independently
modulated as accomplished in the S. pombe system would be of great usefulness in both
testing toxicity and screening compounds for drug development. Ultimately, these should
be perused to the level of mouse models to really test the effects of Gemin2 levels and
provide an advanced platform for any therapeutic testing. Most of these future directions
require, in-and-of-themselves, the amount of work accomplished in typical of a dissertation
or post-doctoral fellowship, but nonetheless stem from the work presented here.
Understanding the work presented here, and especially pursuing some of the ideas
presented for future directions, would greatly advance understanding of RNP biology, the
SMN complex and SMA. The benefit of this for those suffering from this horrible disease
is monumental. These experiments could take a life-time to achieve, but it is my hope that
the field will pick them up and, with a great many hands, address these critical questions,
for advancement of science and the betterment of patients.
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Appendix A Methods
Antibodies and Immunoblotting
The anti-SMN monoclonal antibody 62E7, the anti-Gemin2 monoclonal antibody 2E17,
the anti-Gemin8 monoclonal antibody 13C3 and the anti-Y14 monoclonal antibody 1F12
were described previously.(So et al., 2016; Wan et al., 2005) 1x106 cells of each sample
was resuspended in 40 µl of 2 x SDS loading buffer. 20 µl of the lysate was loaded on a
12.5% SDS-PAGE. Quantitative immunoblotting was performed as described.(So et al.,
2016)

Cell culture and RNAi treatment
HeLa were grown to confluency, harvested by trypinization and counted as described
before.(So et al., 2016; Wan et al., 2008) Cells (2.0 x 106per plate) were treated with RNAi
either control (6 plates), or a mixture of 4 RNAi’s targeting Gemin8 (12 plates) according
to manufacture recommendations (RNAi max, Invitrogen), and allowed to grow for 48
hours before harvesting. Gemin8 RNAi’s sequence is proprietary; however, they can be
ordered under catalog number J-020841-17, J-020841-18, J-020841-19, and J-020841-20
from Dharmacon. Cytoplasm was then extracted from each according to earlier work with
the addition of 5% glycerol for storage only to samples not used in ultracentrifugation.(So
et al., 2016; Wan et al., 2008)

SMA derived lymphoblasts and control cells were

maintained as recomened by the Coriell Institute.
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Electromoblity Shift Assay (EMSA)
Proteins (10-1250 nM) were incubated in buffer (10 µL,150 mM KCl, 10 mM HEPES pH
7.3, 2.5 mM MgCl2, 0.01% NP-40, 100 µg/mL BSA [bovine serum albumen, NEB]) for
15 min 22 C, and then incubated with RNA (5 µL; 100 cmp ~ 10-50 fmol [0.5-2.5 nM]; in
buffer + 300 µg/mL E. coli t-RNAs, 0.3 U/µL RNasine) for and additional 15 min before
being mixed with loading buffer (5 µL; 50% glycerol, 4 M urea, and dyes) and run on a
5% Acrylamide Tris-Glyine, 1 M urea gel at 5 Watts.(Carissimi et al., 2005; Carissimi et
al., 2006; Wan et al., 2008) Gel was vacuum dried and incubated with film for 2 hours in
cassette before being developed.

Electron Microscopy
Crosslinked particles were diluted onto charged 400 mesh copper grids from Aldrich,
blotted and stained with 1% uranyl acetate for 5 secs followed by 3 washes with PBS.
Images were collected by Oris CCD camera at 50000 magnification on a Tecnai TF20
operating at 200 kV. More than 6000 particles from 200 images of a single grid were
selected by hand and processed using RELION 1.3, particles underwent reference free
classification and correction into 100 classes with the bottom 60 being rejected. Particles
from top 40 classes were reclassified into 100 classes, the top 36 of which, representing
2318 particles were used to generate at 3D model.(Scheres, 2016; Sjors H.W. Scheres MRC
Laboratory of Molecular Biology Francis Crick Avenue et al.) Classes were selected for
based on visual appearance and z-score.
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Gemin2 fluorophore labeling and FRET
Gemin2 from S. pombe residues 36-235 with N-terminal His6 tag was labeled for 15 min
at room temperature with NHS-FAM (Lumipobe) as per manufacture recommendations,
at pH 6.0 to ensure amino terminus labeling only. Protein and free fluorophore were
separated on a PD-10 column (GE) as per manufacture recommendations. Labeling
efficiency was measure using a Bio-Rad SmartSpec Plus UV-spectrometer. Most of this
FAM labeled protein was then labeled at Cys 141 with malamide-Cy5 (Lumipobe) for 60
min at room temperature as per manufacture recommendations, and purified and analyzed
as before. 1 µM double-labeled Gemin2 was incubated with 0, 0.2, 0.4, 0.6, 0.8, 1.0, and
1.2 molar excesses of Sm5 and SMN alone and in combination for 60 min 25 C in RSB200
containing 0.05% NP-40 in triplicate as was FAM only labeled Gemin2 in a titration curve.
Fluorescence was measured on a Tecan Spark 10M plate reader excitation 465 and 650 nm
and emissions recorded at 650 and 725 nm at 25 C. FRET efficiencies were measured as
Marti et al. after correction for labeling efficiency and recorded. Distances were also
measured as per Marti et al. with an R0 of 61.4 Å calculated correcting for change in
refractive index of the buffer.(Johnson and Spence, 2010; Martí et al., 2007)
R0 is given by the follow equation:

𝑅"# =

9000(𝑙𝑛 10)𝜅 . 𝐽
128𝜋 . 𝑛3 𝑁56

(1)

Where is the refraction index of the solution, NAv is Avogadro’s number, κ2 is the
orientation factor (2/3 used) and J is a constant for the spectral overlap.
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FRET efficiency is related to fluorescence by the follow equation:

𝐸 =1−

𝑒: 𝐹<=
𝐹<

(2)

Where 𝑒: is the labeling efficiency, 𝐹<= is the fluorescence intensity of FAM in the FAM
cy3 labeled sample, and 𝐹< is the intensity of FAM in only the FAM labeled sample.
FRET efficiency is dependent on the distance by the follow equation:
𝑅"#
𝐸= #
𝑅" + 𝑅#

(3)

Where 𝑅 is the distance between fluorophores, remaining variables are from equation 1.

Hydrophobic mapping and molecular modeling of Gemin2 CTD binding to
peptides
Surface hydrophobicity was mapped onto Gemin2 from 3S6N, using hydrophobic
constants measured by Eisenberg, with a window of 7 and linear decrease in local
hydrophobicity of 25% per residue, residues were color as normalized to maximum
hydrophobicity (L265 score 0.882) as red to 80% grey score ≤ 0.0.(Eisenberg et al., 1984;
Gasteiger et al., 2005; Zhang et al., 2011) Peptides were docked onto amino acids 83-280
of Gemin2 from 3S6N using CABSdock using defaults (50 MC cycles, for 1000
trajectories clustered into 10 clusters) for each peptide: Gemin2 NTD (48-68,
TPQEYLRRVQIEAAQCPDVVV),
IWDDTALIKAYDKAVSFKHAL)
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SMN
and

SmD1

Ge2BD
NTD/RG

(33-54,
(82-103,

DVEPKVKSKKREAVAGRGRGRG) (Kurcinski et al., 2015).(Kurcinski et al., 2015)
Generated models are shown as trajectory most representative of its cluster and ranked
according to number of trajectories weighted by cluster RMSD. Hydrophobic mapping and
docking models were visualized by using PyMol (http://www.pymol.org). Solvent
accessible surface area was recorded for each residue (Using PyMol build-in functions)
and weighted by hydrophobicity score for determining changes in total hydrophobicity, to
determine SMN blocking percentage of residue surface covered by actual SMN and
Gemin2 N-peptide models were compared, maximal results assumed they covered the
same portion of each residue and minimal assumed they cover as different parts of the
residues as they could before overlapping.(Silverman, 2001)
The larger number, maximal percentage shared SASA, assumes that the model and SMN
cover the same area. For example, if in the crystal structure SMA covers 80 of 100 Å2 for
a residue and a model covers 50 Å2 the minimum shared is 37.5% and the maximum is
62.5% (Figure A.1)
The miminal amount of shared area or SMN blocked percentage is given by the follow
equation:

SMN blocked

min

=

𝐴Mod − 𝐴exp − 𝐴SMN
𝐴SMN

(4)

Where 𝐴Mod is the SASA covered by the model peptide, 𝐴exp is the exposed SASA in the
absence of any peptide, and 𝐴SMN is the SASA covered by SMN in the crystal structure.
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The mamimal amount of shared area or SMN blocked percentage is given by the
following equation:

SMN blocked

max

=

𝐴Mod
𝐴SMN

(5)

Where variables are as equation 4.

In vitro protein binding assays
Human and S. pombe proteins (75 pmol [0.4 µM] bait or 375 [2.0 µM] pmol prey) were
incubated in buffer (187.5 µL RSB200 [200 mM NaCl, 50 mM Tris pH 8.0, 5 mM MgCl2,
2 mM TCEP, 0.2 mM EDTA] containing 0.05% NP-40) at 22 °C for 30 min before addition
of magnetic amylose beads (NEB, 18.75 µL 50% in RSB200 containing 0.05% NP-40) for
an additional 30 min incubation at 22 °C. Mixture of the incubations was accomplished
with gentle shaking and inversion. After the incubations, the supernatant removed and the
beads were washed (4 times [187.5 µL RSB200 containing 0.05% NP-40]) and eluted off
amylose beads (20 µL RSB200 containing 0.05% NP-40 and 50 mM Maltose). Samples
were loaded onto SDS-PAGE gel and visualized by silver staining.
S. cerevisiae proteins (300 pmol [3.0-0.8 µM] bait or 600 [6.0-1.6 µM] pmol prey) were
incubated in buffer (100 µL; 150 mM NaCl, 25 mM HEPES pH 7.4, 1 mM TCEP, with
0.01% NP-40) at 22 °C for 15 min before addition of glutathione sepharose beads (GE life,
50 µL 50% in buffer containing 0.01% NP-40) for an additional 15 min incubation at 22
°C. Mixture of the incubations was accomplished with gentle shaking and inversion. After
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the incubations, the supernatant removed and the beads were washed (3 times [500 µL
buffer containing 0.01% NP-40]) and eluted off amylose beads (200 µL buffer containing
0.01% NP-40 and 25 mM glutathione). Samples were precipitated with TCA, resuspended
in SDS-PAGE loading buffer and loaded onto SDS-PAGE gel where they visualized by
silver staining.

Multiple Sequence alignment
Multiple sequence alignments for SMN and Gemin2 were performed for 53 and 178
species respectively with T-coffee espresso with default setting, and represent most of the
orthologs identified.(Notredame et al., 2000)

Plasmid constructs
All human protein expression plasmids are highlighted in our previous work.(So et al.,
2016; Zhang et al., 2011) Plasmids for all S. pombe and S. cerevisieae proteins are as
follows: E. coli optimized sequences were ordered from Genewiz, for spSmD1, and
spSmD3; scSmB.s, scSmD1.s, scSmD2, and scSmF with the addition of a His6-tag and a
TEV cleavage site, for spSmB, spSmD2, spSmE, spSmF, and spSmG; scBrr1, spSmD3;
scSmD3, scSmE, and scSmG. Sequences for spSMN and spGemin2 were cloned from
cDNA, with a maltose binding protein (MBP)-TEV tag incorporated for spSMN (pMALc5x) and His6-TEV for spGemin2, full-length, all mutants, and truncations in pCDFduet1. S. pombe Sm G and E, D1 and D2, and B and D3, were expressed together in pRSFDuet1 (for G,E, and D1,D2) or pACYCDuet-1 (B,D3) plasmids and Sm F in pCDFDuet-1;
however pRSFduet-1(SmG,E) and pCDFDuet-1(SmF) were always co-expressed. S.
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cerevisiae Brr1 was cloned into both pETDuet-1 for EMSAs or pGEX4T-1 for pull-down
for full-length and truncations; Sm G and E, D1.s and D2, and B.s and D3, were expressed
together in pRSFDuet-1 (for F,E), pCDFDuet-1 (B,D3; and F alone) plasmids and
pACYCDuet-1 (D1.s,MBP-D2 [MBP-D2 being cloned out of pMAL-c5x]); however
pRSFduet-1(SmG,E) and pCDFDuet-1(SmF) were always co-expressed. Empty plasmids
were purchased from GE Life Sciences.

Recombinant Protein Purification
All recombinant human proteins were purified as previously described and S. pombe and
S. cerevisiae proteins were purified in a similar way.(So et al., 2016; Zhang et al., 2011)
In brief, all expressing E. coli (BL21 [DE3]) were lysed as previously described with His6
strains also using 500 mM urea. From lysate either HiTrap MBP (SMM), HiTrap GST, or
HisTrap were used follow by ion exchange HiTrap SP HP (D1/D2, B/D3) or HiTrap Q
HP(SMN, Brr1, Gemin2s, SmF/E/G), and finally loaded onto an SD200 16/60 for size
separation and final protein purification. All columns were form GE life Life Science and
used according to manufacturer specifications. Any time concentration was required ion
exchange was used. Purified proteins were checked by SDS-PAGE and stored in 50% (v/v)
glycerol at -80 °C or -20 °C.

RNA production and Labeling
RNA was transcribed as previously described from PCR products and urea TBE gel
purified, 20 pmol was end labeled with 10 mCi 32P[𝛾]-ATP, and stored for use up to 28
days at -20 C.(So et al., 2016; Wan et al., 2008)
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Sedimentation of SMN complexes
The concentration of HeLa cytoplasmic extracts from RNAi treatment was measured using
the Biorad protein assay according to manufacture specifications, which ranged from 4.07.1 mg/mL. 800 µg of each extract was mixed with 10µL of water or FAM-Ge8p (2
mg/mL), in 200 µL. After equilibration of the solution for 30 min at room temperature, the
samples were loaded onto ~4 mL sucrose gradient of 5-20 w/v in the cytoplasmic extract
buffer, and were spun in a SW60 Ti for 180 min at 4°C and 207 500 RFC.(Battle et al.,
2006) Fractions (37, 100 µL) were collected for each sample along with a pellet fraction
of 300-400 µL at the bottom of the tube. These fractions were then immediately assayed
for FAM-Ge8p using a Victor2V 1420 multilabel counter 0.1 s fluorescence counter,
excitation 485 nm, fluorescence 535 nm, before samples were mixed with SDS sample
buffer and loaded onto a 4-12% bis-tris NuPAGE gel (Invitrogen).

Strain production and growth for S. pombe
S. pombe strain XYZ was used as wild-type and base, SG1 used homologous replacement
via pop-in pop-out to replace SMN promotor with Tet-off from pDM291. SG1 served as
the basis for SG2 where yip12 ws replaced with pUG6 (KanMX6 marker); similarly, yip11
promotor was changed to nmt81 with pFA6a-hphMXG-P81mnt1-3FLAG for SG3 from
SG2. These were constructed as previously reported.(Bähler et al., 1998; Forsburg, 2001)
Cells were grown on EMM media supplemented with His, Lue, and Ura, and included 6.5
mg/L thiamine and/or 7.0 mg/L doxycycline as indicated. Cells were maintained in solution
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with EMM and pretreated 24hrs before plating with appropriate thiamine or doxycycline.
Plates were cultured for 72 hr. at 30 before imaging via scanner. Primers were the follow:
SMN1_f:
GAAATATGTTATGATAGTTTTTCATGAACGAAAATCTTTAAAATATGAATGTA
TGTAGAGGAGGGATAGTAGAACGATACGAATTCGAGCTCGTTTAAAC
SMN1_r:
TTTTTGAATTCATGTAAAGCGGTTTCAAAGGCATTTCTGAGCTCTGAATCATC
CCACACTTCTTTTTGGCTCTGGTCCATTCCGCCTCCTTTATCATCAT
tetR_20_f: ATGTCTAGATTAGATAAAAG
tetR_566c_r: ATATGATCAATTCAAGGC
yip11_-122_pUG_f:
GAGTATTTTCATGAAAATTCGGTAATTCTTTTCCATTTGGTTTATATGAGAAG
TTTGCAATTGTACAATAATAATTCAAACAGCTGAAGCTTCGTACGC
yip11_2176c_pUG_r:
CTATGATGCTTTCTTTTTCTGGCAACTCTTCCCATTGTCCGTCACTTCAAACAA
ACCCGTTTACCACAATTACAATGTTGCATAGGCCACTAGTGGATCT
yip12_pFA6a_f:
GAGTATTTTCATGAAAATTCGGTAATTCTTTTCCATTTGGTTTATATGAGAAG
TTTGCAATTGTACAATAATAATTCAAAGAATTCGAGCTCGTTTAAAC
149

yip12_pFA6a_r:
GCGCTGCGTTGATTTGTTTCCTCATCTAATGATCCTGAAGTCTGATATTGTAA
AGGATTTCTTTTTCTTTTCGAGGGCATAGACATGATTTAACAAAGCG

150

Figure A.1 Diagram of example minimal and maximal model-SMN overlap
(A) The SASA covered by SMN (blue) and a model (red). total SASA residue area is within
the circle with white being uncovered. (B) Maximal coverage which assumes all of the
model that can cover the same area as SMN does. Mutually covered areas shown in purple
and leaves some SASA covered by neither. (C) Mimimal coverage assumes that the model
covers any area SMN does not before covering mutual areas (purple). Areas are given as
examples with the resulting percentage blocked displayed below.
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80 Å²
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20 Å²

B.

50 Å²
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50Å²
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